<?xml version="1.0" encoding="utf-8"?>
<xbrl
  xmlns="http://www.xbrl.org/2003/instance"
  xmlns:crvw="http://careviewinc.com/20220331"
  xmlns:dei="http://xbrl.sec.gov/dei/2021q4"
  xmlns:iso4217="http://www.xbrl.org/2003/iso4217"
  xmlns:link="http://www.xbrl.org/2003/linkbase"
  xmlns:srt="http://fasb.org/srt/2021-01-31"
  xmlns:us-gaap="http://fasb.org/us-gaap/2021-01-31"
  xmlns:utr="http://www.xbrl.org/2009/utr"
  xmlns:xbrldi="http://xbrl.org/2006/xbrldi"
  xmlns:xlink="http://www.w3.org/1999/xlink"
  xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">
    <link:schemaRef xlink:href="crvw-20220331.xsd" xlink:type="simple"/>
    <context id="From2022-01-01to2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-05-23">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2022-05-23</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeniorSecuredNotesRelatedPartyCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeniorSecuredNotesRelatedPartyCurrentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyCurrentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeniorSecuredNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeniorSecuredNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeniorSecuredConvertibleNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeniorSecuredConvertibleNotesRelatedPartyMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesRelatedPartyMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SeniorSecuredConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SeniorSecuredConvertibleNotesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:SeniorSecuredConvertibleNotesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SubscriptionBasedLeaseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SubscriptionBasedLeaseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SubscriptionBasedLeaseRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SubscriptionBasedLeaseRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SalesBasedEquipmentPackageRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedEquipmentPackageRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SalesBasedEquipmentPackageRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedEquipmentPackageRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SalesBasedSoftwareBundleRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedSoftwareBundleRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SalesBasedSoftwareBundleRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedSoftwareBundleRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:AdditionalPaidInCapitalMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_RetainedEarningsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:RetainedEarningsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SalesBasedContractRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SalesBasedContractRevenueMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:ProductOrServiceAxis">crvw:SalesBasedContractRevenueMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SubscriptionBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SubscriptionBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2020-12-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2020-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-03-31_custom_SalesBasisContractMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ContractWithCustomerBasisOfPricingAxis">crvw:SalesBasisContractMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_YearOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:PerformanceDateAxis">crvw:YearOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_YearTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:PerformanceDateAxis">crvw:YearTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_YearThreeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="crvw:PerformanceDateAxis">crvw:YearThreeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-08_custom_HealthCorAllongeNo4WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorAllongeNo4WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-08</instant>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorPartnersWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorPartnersWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorHybridWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorHybridWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ExercisePriceOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvw:ExercisePriceOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_ExercisePriceTwoMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis">crvw:ExercisePriceTwoMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_WarrantMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_WarrantMember_srt_MinimumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MinimumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_WarrantMember_srt_MaximumMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:RangeAxis">srt:MaximumMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">us-gaap:WarrantMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_NetworkEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:NetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_NetworkEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:NetworkEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OfficeEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:OfficeEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_VehiclesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:VehiclesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_TestEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:TestEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_TestEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:TestEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:FurnitureAndFixturesMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_WarehouseEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:WarehouseEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_WarehouseEquipmentMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">crvw:WarehouseEquipmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:PropertyPlantAndEquipmentByTypeAxis">us-gaap:LeaseholdImprovementsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_PatentsTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">crvw:PatentsTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PatentsTrademarksMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">crvw:PatentsTrademarksMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_us-gaap_OtherIntangibleAssetsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:FiniteLivedIntangibleAssetsByMajorClassAxis">us-gaap:OtherIntangibleAssetsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_DeferredInstallationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:DeferredInstallationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_DeferredSalesCommissionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:DeferredSalesCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_PrepaidLicenseFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:PrepaidLicenseFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DeferredInstallationCostsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:DeferredInstallationCostsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_DeferredSalesCommissionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:DeferredSalesCommissionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_PrepaidLicenseFeeMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:PrepaidLicenseFeeMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="AsOf2021-12-31_custom_SecurityDepositMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:BalanceSheetLocationAxis">crvw:SecurityDepositMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-12-31</instant>
        </period>
    </context>
    <context id="From2017-01-012017-12-31_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2017-01-01</startDate>
            <endDate>2017-12-31</endDate>
        </period>
    </context>
    <context id="From2018-01-012018-12-31_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2018-01-01</startDate>
            <endDate>2018-12-31</endDate>
        </period>
    </context>
    <context id="AsOf2018-01-02_us-gaap_InternalRevenueServiceIRSMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:IncomeTaxAuthorityAxis">us-gaap:InternalRevenueServiceIRSMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2018-01-02</instant>
        </period>
    </context>
    <context id="AsOf2015-06-26_custom_PDLBioPharmaIncMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-26</instant>
        </period>
    </context>
    <context id="AsOf2015-06-26_custom_PDLBioPharmaIncMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2015-06-26</instant>
        </period>
    </context>
    <context id="From2015-10-082019-05-13_custom_PDLBioPharmaIncMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2015-10-08</startDate>
            <endDate>2019-05-13</endDate>
        </period>
    </context>
    <context id="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:TrancheOneMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2019-05-15</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_PDLBioPharmaIncMember_custom_WarrantPurchaseAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:WarrantPurchaseAgreementMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:CreditFacilityAxis">crvw:PDLBioPharmaIncMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_PDLModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:PDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_PDLModificationAgreementMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:PDLModificationAgreementMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-04-21</instant>
        </period>
    </context>
    <context id="AsOf2011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2011-04-21</instant>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">us-gaap:ConvertibleDebtMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt1Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_FirstFiveYearNotePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">crvw:FirstFiveYearNotePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_SecondFiveYearNotePeriodMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt2Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:VariableRateAxis">crvw:SecondFiveYearNotePeriodMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:LongtermDebtTypeAxis">crvw:ConvertibleDebt2Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2011-04-20</startDate>
            <endDate>2011-04-21</endDate>
        </period>
    </context>
    <context id="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-17</startDate>
            <endDate>2021-04-18</endDate>
        </period>
    </context>
    <context id="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-17</startDate>
            <endDate>2021-04-18</endDate>
        </period>
    </context>
    <context id="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2012Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-04-19</startDate>
            <endDate>2021-04-20</endDate>
        </period>
    </context>
    <context id="AsOf2021-04-20_custom_HealthCorNoteExtensionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2021-04-20</instant>
        </period>
    </context>
    <context id="From2022-03-052022-03-06_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-05</startDate>
            <endDate>2022-03-06</endDate>
        </period>
    </context>
    <context id="From2022-03-072022-03-08_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-08</endDate>
        </period>
    </context>
    <context id="From2022-03-072022-03-08_custom_HealthCorNoteExtensionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-03-07</startDate>
            <endDate>2022-03-08</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-08_custom_HealthCorNoteExtensionsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCorNoteExtensionsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-08</instant>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_Notes2011Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:Notes2011Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="From2022-01-012022-03-31_custom_HealthCor3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2022-01-01</startDate>
            <endDate>2022-03-31</endDate>
        </period>
    </context>
    <context id="From2021-01-012021-03-31_custom_HealthCor3Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-01-01</startDate>
            <endDate>2021-03-31</endDate>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCorNinthAmendmentWarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorNinthAmendmentWarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCorAllongeNo3WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorAllongeNo3WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCorAllongeNo4WarrantsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="us-gaap:ClassOfWarrantOrRightAxis">crvw:HealthCorAllongeNo4WarrantsMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2014Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:HealthCorNotes2014Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:Investors2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2015Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:HealthCorNotes2015Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2018InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:February2018InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_July2018InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:July2018InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2019Member">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:Investors2019Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2020InvestorsMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="srt:TitleOfIndividualAxis">crvw:February2020InvestorsMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:HealthCor3Member</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:StatementEquityComponentsAxis">us-gaap:CommonStockMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <instant>2022-03-31</instant>
        </period>
    </context>
    <context id="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:SecondRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2019-12-30</startDate>
            <endDate>2019-12-31</endDate>
        </period>
    </context>
    <context id="From2020-01-302020-01-31_custom_RockwellMember_custom_ThirdRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:ThirdRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-01-30</startDate>
            <endDate>2020-01-31</endDate>
        </period>
    </context>
    <context id="From2020-03-302020-03-31_custom_RockwellMember_custom_FourthRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:FourthRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-03-30</startDate>
            <endDate>2020-03-31</endDate>
        </period>
    </context>
    <context id="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:FifthRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2020-12-30</startDate>
            <endDate>2020-12-31</endDate>
        </period>
    </context>
    <context id="From2021-11-292021-11-30_custom_RockwellMember_custom_SixthRockwellNoteAmendmentMember_custom_RockwellNoteMember">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
            <segment>
                <xbrldi:explicitMember dimension="srt:CounterpartyNameAxis">crvw:RockwellMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:DebtInstrumentAxis">crvw:RockwellNoteMember</xbrldi:explicitMember>
                <xbrldi:explicitMember dimension="us-gaap:TypeOfArrangementAxis">crvw:SixthRockwellNoteAmendmentMember</xbrldi:explicitMember>
            </segment>
        </entity>
        <period>
            <startDate>2021-11-29</startDate>
            <endDate>2021-11-30</endDate>
        </period>
    </context>
    <context id="AsOf2009-09-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2009-09-08</instant>
        </period>
    </context>
    <context id="From2009-09-072009-09-08">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2009-09-07</startDate>
            <endDate>2009-09-08</endDate>
        </period>
    </context>
    <context id="From2020-03-032020-03-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <startDate>2020-03-03</startDate>
            <endDate>2020-03-04</endDate>
        </period>
    </context>
    <context id="AsOf2020-03-04">
        <entity>
            <identifier scheme="http://www.sec.gov/CIK">0001377149</identifier>
        </entity>
        <period>
            <instant>2020-03-04</instant>
        </period>
    </context>
    <unit id="USD">
        <measure>iso4217:USD</measure>
    </unit>
    <unit id="Shares">
        <measure>shares</measure>
    </unit>
    <unit id="USDPShares">
        <divide>
            <unitNumerator>
                <measure>iso4217:USD</measure>
            </unitNumerator>
            <unitDenominator>
                <measure>shares</measure>
            </unitDenominator>
        </divide>
    </unit>
    <unit id="Pure">
        <measure>pure</measure>
    </unit>
    <unit id="Sqft">
        <measure>utr:sqft</measure>
    </unit>
    <dei:EntityCentralIndexKey contextRef="From2022-01-01to2022-03-31">0001377149</dei:EntityCentralIndexKey>
    <dei:AmendmentFlag contextRef="From2022-01-01to2022-03-31">false</dei:AmendmentFlag>
    <dei:DocumentFiscalYearFocus contextRef="From2022-01-01to2022-03-31">2022</dei:DocumentFiscalYearFocus>
    <dei:DocumentFiscalPeriodFocus contextRef="From2022-01-01to2022-03-31">Q1</dei:DocumentFiscalPeriodFocus>
    <dei:CurrentFiscalYearEndDate contextRef="From2022-01-01to2022-03-31">--12-31</dei:CurrentFiscalYearEndDate>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0095"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ConvertibleDebtNoncurrent
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0114"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0146"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PreferredStockValue
      contextRef="AsOf2021-12-31"
      id="xdx2ixbrl0147"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0236"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0239"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0248"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncomeTaxExpenseBenefit
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0249"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0275"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0277"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0280"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0281"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0298"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0300"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0303"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      id="xdx2ixbrl0305"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_CommonStockMember"
      id="xdx2ixbrl0308"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      id="xdx2ixbrl0309"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0340"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0377"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0386"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0389"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2022-01-012022-03-31_custom_SubscriptionBasisContractMember"
      id="xdx2ixbrl0442"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2022-03-31"
      decimals="0"
      id="xdx2ixbrl0469"
      unitRef="USD">1394694</us-gaap:RevenueRemainingPerformanceObligation>
    <crvw:AdditionsToDeferredCosts
      contextRef="From2022-01-01to2022-03-31"
      id="xdx2ixbrl0484"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:AdditionsToDeferredCosts
      contextRef="From2021-01-012021-03-31"
      id="xdx2ixbrl0485"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:RetainedEarningsAccumulatedDeficit
      contextRef="AsOf2022-03-31"
      decimals="0"
      id="xdx2ixbrl0505"
      unitRef="USD">-200235054</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      id="xdx2ixbrl0507"
      unitRef="USD">-323224</us-gaap:OperatingIncomeLoss>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_custom_TestEquipmentMember"
      id="xdx2ixbrl0632"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31_us-gaap_OtherIntangibleAssetsMember"
      id="xdx2ixbrl0674"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_SecurityDepositMember"
      id="xdx2ixbrl0693"
      unitRef="USD"
      xsi:nil="true"/>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_SecurityDepositMember"
      id="xdx2ixbrl0708"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="AsOf2022-03-31"
      id="xdx2ixbrl0739"
      unitRef="USD"
      xsi:nil="true"/>
    <us-gaap:LesseeOperatingLeaseRenewalTerm contextRef="AsOf2020-03-04" id="xdx2ixbrl0870">P5Y</us-gaap:LesseeOperatingLeaseRenewalTerm>
    <us-gaap:OperatingLeaseLiability
      contextRef="AsOf2022-03-31"
      decimals="0"
      id="xdx2ixbrl0921"
      unitRef="USD">578298</us-gaap:OperatingLeaseLiability>
    <dei:DocumentType contextRef="From2022-01-01to2022-03-31">10-Q</dei:DocumentType>
    <dei:DocumentQuarterlyReport contextRef="From2022-01-01to2022-03-31">true</dei:DocumentQuarterlyReport>
    <dei:DocumentPeriodEndDate contextRef="From2022-01-01to2022-03-31">2022-03-31</dei:DocumentPeriodEndDate>
    <dei:DocumentTransitionReport contextRef="From2022-01-01to2022-03-31">false</dei:DocumentTransitionReport>
    <dei:EntityFileNumber contextRef="From2022-01-01to2022-03-31">000-54090</dei:EntityFileNumber>
    <dei:EntityRegistrantName contextRef="From2022-01-01to2022-03-31">CAREVIEW COMMUNICATIONS, INC.</dei:EntityRegistrantName>
    <dei:EntityIncorporationStateCountryCode contextRef="From2022-01-01to2022-03-31">NV</dei:EntityIncorporationStateCountryCode>
    <dei:EntityTaxIdentificationNumber contextRef="From2022-01-01to2022-03-31">95-4659068</dei:EntityTaxIdentificationNumber>
    <dei:EntityAddressAddressLine1 contextRef="From2022-01-01to2022-03-31">405 State Highway 121</dei:EntityAddressAddressLine1>
    <dei:EntityAddressAddressLine2 contextRef="From2022-01-01to2022-03-31">Suite B-240</dei:EntityAddressAddressLine2>
    <dei:EntityAddressCityOrTown contextRef="From2022-01-01to2022-03-31">Lewisville</dei:EntityAddressCityOrTown>
    <dei:EntityAddressStateOrProvince contextRef="From2022-01-01to2022-03-31">TX</dei:EntityAddressStateOrProvince>
    <dei:EntityAddressPostalZipCode contextRef="From2022-01-01to2022-03-31">75067</dei:EntityAddressPostalZipCode>
    <dei:CityAreaCode contextRef="From2022-01-01to2022-03-31">(972)</dei:CityAreaCode>
    <dei:LocalPhoneNumber contextRef="From2022-01-01to2022-03-31">943-6050</dei:LocalPhoneNumber>
    <dei:EntityCurrentReportingStatus contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityCurrentReportingStatus>
    <dei:EntityInteractiveDataCurrent contextRef="From2022-01-01to2022-03-31">Yes</dei:EntityInteractiveDataCurrent>
    <dei:EntityFilerCategory contextRef="From2022-01-01to2022-03-31">Non-accelerated Filer</dei:EntityFilerCategory>
    <dei:EntitySmallBusiness contextRef="From2022-01-01to2022-03-31">true</dei:EntitySmallBusiness>
    <dei:EntityEmergingGrowthCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityEmergingGrowthCompany>
    <dei:EntityShellCompany contextRef="From2022-01-01to2022-03-31">false</dei:EntityShellCompany>
    <dei:EntityCommonStockSharesOutstanding contextRef="AsOf2022-05-23" decimals="INF" unitRef="Shares">139380748</dei:EntityCommonStockSharesOutstanding>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">764707</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:CashAndCashEquivalentsAtCarryingValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">659228</us-gaap:CashAndCashEquivalentsAtCarryingValue>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1090994</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:AccountsReceivableNetCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">933200</us-gaap:AccountsReceivableNetCurrent>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">269917</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">349216</us-gaap:InventoryNet>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">122383</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">235521</us-gaap:OtherAssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">2248001</us-gaap:AssetsCurrent>
    <us-gaap:AssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">2177165</us-gaap:AssetsCurrent>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1003951</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1138891</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">952056</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">910398</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">526652</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">555150</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">283393</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">299563</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1762101</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:OtherAssetsNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1765111</us-gaap:OtherAssetsNoncurrent>
    <us-gaap:Assets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5014053</us-gaap:Assets>
    <us-gaap:Assets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5081167</us-gaap:Assets>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">453869</us-gaap:AccountsPayableCurrent>
    <us-gaap:AccountsPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">414333</us-gaap:AccountsPayableCurrent>
    <us-gaap:OtherShortTermBorrowings contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">20000000</us-gaap:OtherShortTermBorrowings>
    <us-gaap:OtherShortTermBorrowings contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">20013786</us-gaap:OtherShortTermBorrowings>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">700000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:NotesPayableRelatedPartiesClassifiedCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">700000</us-gaap:NotesPayableRelatedPartiesClassifiedCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2022-03-31_custom_SeniorSecuredNotesRelatedPartyCurrentMember"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-12-31_custom_SeniorSecuredNotesRelatedPartyCurrentMember"
      decimals="0"
      unitRef="USD">307831</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DueToOtherRelatedPartiesClassifiedCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">56302303</us-gaap:DueToOtherRelatedPartiesClassifiedCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">165741</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">162470</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">12755753</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11740218</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">34075363</us-gaap:LiabilitiesCurrent>
    <us-gaap:LiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">89333110</us-gaap:LiabilitiesCurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2022-03-31_custom_SeniorSecuredNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">372270</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-12-31_custom_SeniorSecuredNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">0</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:ConvertibleDebtNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">56237865</us-gaap:ConvertibleDebtNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2022-03-31_custom_SeniorSecuredConvertibleNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">2345746</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleNotesRelatedPartyMember"
      decimals="0"
      unitRef="USD">2562161</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">25226730</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DueToRelatedPartiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">24302135</us-gaap:DueToRelatedPartiesNoncurrent>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2022-03-31_custom_SeniorSecuredConvertibleNotesMember"
      decimals="0"
      unitRef="USD">225341</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet
      contextRef="AsOf2021-12-31_custom_SeniorSecuredConvertibleNotesMember"
      decimals="0"
      unitRef="USD">240125</us-gaap:DebtInstrumentUnamortizedDiscountPremiumAndDebtIssuanceCostsNet>
    <us-gaap:SecuredLongTermDebt contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">3774948</us-gaap:SecuredLongTermDebt>
    <us-gaap:SecuredLongTermDebt contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">3661617</us-gaap:SecuredLongTermDebt>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">412557</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">445033</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">34049</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:OtherLiabilitiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">37570</us-gaap:OtherLiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">85686149</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:LiabilitiesNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">28446355</us-gaap:LiabilitiesNoncurrent>
    <us-gaap:Liabilities contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">119761512</us-gaap:Liabilities>
    <us-gaap:Liabilities contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">117779465</us-gaap:Liabilities>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:PreferredStockParOrStatedValuePerShare>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">20000000</us-gaap:PreferredStockSharesAuthorized>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesIssued>
    <us-gaap:PreferredStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">0</us-gaap:PreferredStockSharesOutstanding>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockParOrStatedValuePerShare
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.001</us-gaap:CommonStockParOrStatedValuePerShare>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesAuthorized contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">500000000</us-gaap:CommonStockSharesAuthorized>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesIssued contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesIssued>
    <us-gaap:CommonStockSharesOutstanding contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">139380748</us-gaap:CommonStockSharesOutstanding>
    <us-gaap:CommonStockValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">139381</us-gaap:CommonStockValue>
    <us-gaap:CommonStockValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">139381</us-gaap:CommonStockValue>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">85348214</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:AdditionalPaidInCapitalCommonStock contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">85052367</us-gaap:AdditionalPaidInCapitalCommonStock>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-200235054</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:RetainedEarningsAccumulatedDeficit contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-197890046</us-gaap:RetainedEarningsAccumulatedDeficit>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-114747459</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-112698298</us-gaap:StockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">5014053</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:LiabilitiesAndStockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">5081167</us-gaap:LiabilitiesAndStockholdersEquity>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SubscriptionBasedLeaseRevenueMember"
      decimals="0"
      unitRef="USD">1307863</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SubscriptionBasedLeaseRevenueMember"
      decimals="0"
      unitRef="USD">1350043</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SalesBasedEquipmentPackageRevenueMember"
      decimals="0"
      unitRef="USD">817012</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SalesBasedEquipmentPackageRevenueMember"
      decimals="0"
      unitRef="USD">979977</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SalesBasedSoftwareBundleRevenueMember"
      decimals="0"
      unitRef="USD">194154</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SalesBasedSoftwareBundleRevenueMember"
      decimals="0"
      unitRef="USD">34863</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2319029</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">2364883</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:EquipmentExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">117598</us-gaap:EquipmentExpense>
    <us-gaap:EquipmentExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">43799</us-gaap:EquipmentExpense>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">737476</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:CommunicationsAndInformationTechnology
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">721568</us-gaap:CommunicationsAndInformationTechnology>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">939248</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:GeneralAndAdministrativeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">723742</us-gaap:GeneralAndAdministrativeExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">189216</us-gaap:SellingAndMarketingExpense>
    <us-gaap:SellingAndMarketingExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">100599</us-gaap:SellingAndMarketingExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">497252</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:ResearchAndDevelopmentExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">386080</us-gaap:ResearchAndDevelopmentExpense>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">161463</us-gaap:DepreciationAndAmortization>
    <us-gaap:DepreciationAndAmortization
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">162820</us-gaap:DepreciationAndAmortization>
    <us-gaap:OperatingExpenses
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2642253</us-gaap:OperatingExpenses>
    <us-gaap:OperatingExpenses
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">2138608</us-gaap:OperatingExpenses>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-323224</us-gaap:OperatingIncomeLoss>
    <us-gaap:OperatingIncomeLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">226276</us-gaap:OperatingIncomeLoss>
    <us-gaap:InterestExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2021784</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">2713846</us-gaap:InterestExpense>
    <us-gaap:InvestmentIncomeInterest
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">50</us-gaap:InvestmentIncomeInterest>
    <us-gaap:OtherNonoperatingIncome
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">269</us-gaap:OtherNonoperatingIncome>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2021784</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:NonoperatingIncomeExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2713527</us-gaap:NonoperatingIncomeExpense>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2345008</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2487251</us-gaap:IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2345008</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2487251</us-gaap:ProfitLoss>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="2"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2022-01-01to2022-03-31"
      decimals="2"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:EarningsPerShareBasic
      contextRef="From2021-01-012021-03-31"
      decimals="2"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareBasic>
    <us-gaap:EarningsPerShareDiluted
      contextRef="From2021-01-012021-03-31"
      decimals="2"
      unitRef="USDPShares">-0.02</us-gaap:EarningsPerShareDiluted>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:WeightedAverageNumberOfSharesOutstandingBasic
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfSharesOutstandingBasic>
    <us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="Shares">139380748</us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84409372</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2020-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-187809683</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">-103260930</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">52878</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">52878</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2487251</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2487251</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">84462250</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-190296934</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">-105695303</us-gaap:StockholdersEquity>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">85052367</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2021-12-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-197890046</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">-112698298</us-gaap:StockholdersEquity>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">240000</us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-012022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">55847</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">55847</us-gaap:AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-012022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-2345008</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2345008</us-gaap:ProfitLoss>
    <us-gaap:SharesOutstanding
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">139380748</us-gaap:SharesOutstanding>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_CommonStockMember"
      decimals="0"
      unitRef="USD">139381</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_AdditionalPaidInCapitalMember"
      decimals="0"
      unitRef="USD">85348214</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity
      contextRef="AsOf2022-03-31_us-gaap_RetainedEarningsMember"
      decimals="0"
      unitRef="USD">-200235054</us-gaap:StockholdersEquity>
    <us-gaap:StockholdersEquity contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">-114747459</us-gaap:StockholdersEquity>
    <us-gaap:ProfitLoss
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-2345008</us-gaap:ProfitLoss>
    <us-gaap:ProfitLoss
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2487251</us-gaap:ProfitLoss>
    <us-gaap:Depreciation
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">134940</us-gaap:Depreciation>
    <us-gaap:Depreciation
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">149902</us-gaap:Depreciation>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">14451</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfIntangibleAssets
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">12918</us-gaap:AmortizationOfIntangibleAssets>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">166760</us-gaap:AmortizationOfDebtDiscountPremium>
    <us-gaap:AmortizationOfDebtDiscountPremium
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">1166558</us-gaap:AmortizationOfDebtDiscountPremium>
    <crvw:AmortizationOfInstallationCosts
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">12072</crvw:AmortizationOfInstallationCosts>
    <crvw:AmortizationOfInstallationCosts
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">9442</crvw:AmortizationOfInstallationCosts>
    <us-gaap:AmortizationOfFinancingCosts
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">14451</us-gaap:AmortizationOfFinancingCosts>
    <crvw:NoncashLeaseExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">28499</crvw:NoncashLeaseExpense>
    <crvw:NoncashLeaseExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">788</crvw:NoncashLeaseExpense>
    <us-gaap:PaidInKindInterest
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">806728</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">721825</us-gaap:PaidInKindInterest>
    <us-gaap:ShareBasedCompensation
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">295847</us-gaap:ShareBasedCompensation>
    <us-gaap:ShareBasedCompensation
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">52878</us-gaap:ShareBasedCompensation>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">157794</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInAccountsReceivable
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">4418</us-gaap:IncreaseDecreaseInAccountsReceivable>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-79299</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInInventories
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-24086</us-gaap:IncreaseDecreaseInInventories>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-113138</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInOtherCurrentAssets
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-134233</us-gaap:IncreaseDecreaseInOtherCurrentAssets>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-4099</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-4098</us-gaap:IncreaseDecreaseInIntangibleAssetsCurrent>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">39536</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccountsPayable
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-329212</us-gaap:IncreaseDecreaseInAccountsPayable>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">688005</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">809200</us-gaap:IncreaseDecreaseInAccruedLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">327529</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-232009</us-gaap:IncreaseDecreaseInAccruedLiabilitiesAndOtherOperatingLiabilities>
    <us-gaap:IncreaseDecreaseInOperatingLeaseLiability
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-29205</us-gaap:IncreaseDecreaseInOperatingLeaseLiability>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">178896</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">47489</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:PaymentsToAcquireIntangibleAssets
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">56110</us-gaap:PaymentsToAcquireIntangibleAssets>
    <us-gaap:NetCashProvidedByUsedInInvestingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-56110</us-gaap:NetCashProvidedByUsedInInvestingActivities>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">17307</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:RepaymentsOfNotesPayable
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">50000</us-gaap:RepaymentsOfNotesPayable>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">-17307</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:NetCashProvidedByUsedInFinancingActivities
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-50000</us-gaap:NetCashProvidedByUsedInFinancingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">105479</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">-2511</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">659228</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">357950</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">764707</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">355439</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_807_eus-gaap--BasisOfPresentationAndSignificantAccountingPoliciesTextBlock_zhL9Fse16W8g" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 0 0.75in; text-indent: -0.75in"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 1 &#x2013; &lt;span id="xdx_820_zyeESHHP6rq3"&gt;BASIS OF PRESENTATION
AND RECENTLY ISSUED ACCOUNTING PRONOUNCEMENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zk9Tx8ii9Id1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zD6cd6L2Y1Gd"&gt;Interim Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited interim condensed
consolidated financial statements of CareView Communications, Inc. ("CareView", the "Company", "we",
"us" or "our") have been prepared in accordance with generally accepted accounting principles in the United States
of America ("GAAP") for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not
include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such
financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of
the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange
Commission (the "SEC"). The balance sheet at December 31, 2021 has been derived from the audited consolidated financial
statements at that date but does not include all of the information and footnotes required by GAAP for complete financial
statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those
estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying
unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial
statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC
on March 31, 2022.&lt;/p&gt;

&lt;p id="xdx_85D_zM1BYMlXd0il" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zbQME6RX58T3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zOdaI8yDg916"&gt;Revenue Recognition&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize revenue in accordance with Accounting
Standards Codification (&#x201c;ASC&#x201d;) Topic 606 (&#x201c;ASC 606&#x201d;). For our subscription service contracts, we have employed
the practical expedient discussed in ASC 606-10-55-18 related to invoicing as we have the right to consideration from our customers in
the amount that corresponds directly with the value to the customer of our performance completed to date and therefore, we recognize revenue
upon invoicing as further discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;br/&gt;
In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue
recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions
of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers
in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply
the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine
the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when,
or as, we satisfy the performance obligation. For those customers for which we are required to collect sales taxes, we record such sales
taxes on a net basis which has no effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the
taxing authority.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We enter into contracts with customers that may provide
multiple combinations of our products, software solutions, and other related services, which are generally capable of being distinct and
accounted for as separate performance obligations. Performance obligations that are not distinct at contract inception are combined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Customer contract fulfillment typically involves
multiple procurement promises, which may include various equipment, software subscription, project-related installation and training
services, and support. We allocate the transaction price to each performance obligation based on estimated relative standalone
selling price. Revenue is then recognized for each performance obligation upon transferring control of the hardware, software, and
services to the customer and in an amount that reflects the consideration we expect to receive and the estimated benefit the
customer receives over the term of the contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Generally, we recognize revenue under each of our
performance obligations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subscription services &#x2013;
We recognize subscription revenues monthly over the contracted license period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment packages &#x2013; We
recognize equipment revenues when control of the devices has been transferred to the client (&#x201c;point in time&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software bundle and related
services related to sales-based contracts &#x2013; We recognize our software subscription, installation, training, and other services on
a straight-line basis over the estimated contracted license period (&#x201c;over time&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zeXAVAydEsue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zJUszMfrftol"&gt;The following presents gross revenues disaggregated
by our business models:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Sales-based contract revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&#160;&#160;Equipment package, net (point in time)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedEquipmentPackageRevenueMember_zDsF0CWqcmM1" style="width: 12%; text-align: right" title="Gross revenue"&gt;817,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedEquipmentPackageRevenueMember_z2IpSdHV1pPi" style="width: 12%; text-align: right" title="Gross revenue"&gt;979,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Software bundle (over time)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedSoftwareBundleRevenueMember_zKyVxdvgYQrk" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;194,154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedSoftwareBundleRevenueMember_zeXVQrkdtVDb" style="border-bottom: Black 1pt solid; text-align: right"&gt;34,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Total sales-based contract revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zE8RhGSuNToc" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;1,011,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zQESAmze0C0g" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,014,840&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Subscription-based lease revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SubscriptionBasedLeaseRevenueMember_zD47GtK2O5mk" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;1,307,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SubscriptionBasedLeaseRevenueMember_z1vBzb1ORKx3" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,350,043&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;Gross revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20220101__20220331_zyZVE4QT08oe" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross revenue"&gt;2,319,029&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20210101__20210331_z5jGtq3t2spe" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,364,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zgtqffh3Qsui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our subscription-based contracts payment arrangements
are required to be paid monthly which are recognized into revenue when received. Some customers choose to pay their subscription fee in
advance. Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities.
These amounts are recorded as &#x201c;deferred revenue&#x201d; in our condensed consolidated balance sheet and recognized into revenues
over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our sales-based contract payment arrangements with
our customers typically include an initial equipment payment due upon signing of the contract and subsequent payments when certain performance
obligations are completed. Customer payments received in advance of satisfaction of related performance obligations are deferred as contract
liabilities. These amounts are recorded as &#x201c;deferred revenue&#x201d; in our condensed consolidated balance sheet and recognized
into revenues as either a point in time or over time.&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zo6CXmIXJWX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2022 and 2021,
a total of $&lt;span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_z1pLhstRMdIh" title="Contract liability recognized as revenue"&gt;83,194&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_znUoFMlJa9y2" title="Contract liability recognized as revenue"&gt;67,165&lt;/span&gt; respectively, of the beginning balance of the subscription-based contract liability was recognized as revenue.
&lt;span id="xdx_8B5_z0WhjzXY5nt8"&gt;The table below details the subscription-based contract liability activity&lt;/span&gt; during the three months ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zuTM89dRUzjj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zLEi32Ztmerc" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_ztuZW3hI9ioh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;231,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;238,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityAdditions_zD1uxo7o2pFg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0442"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_z0o6rrztC283" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(83,194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(78,819&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ContractWithCustomerLiability_iE_zusWYl9Hl8x4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;147,946&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;229,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2022 and 2021,
a total of $&lt;span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pp0p0_c20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zpQCbdlnWdRe" title="Contract liability recognized as revenue"&gt;490,374&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zollTy6K9Qzg" title="Contract liability recognized as revenue"&gt;166,880&lt;/span&gt;, respectively, of the beginning balance of the sales-based contract liability was recognized as revenue.
The table below details the sales-based contract liability activity during the three months ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zzB6eY3Ypgaa" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zZ9bNU2jr7V1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zeYiyepSgPs4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;752,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;226,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityAdditions_zPSF0RTp8W0i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;939,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zvDcPjKuTD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,011,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,014,841&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ContractWithCustomerLiability_iE_zimA1aV61Q3l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,246,747&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;151,048&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zFYyu6TBnIV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_zQFGd1DbzISa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8B1_z82amqUx9yT5"&gt;As of March 31, 2022, the aggregate amount of deferred
revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied or partially
satisfied&lt;/span&gt; is approximately $&lt;span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_dxL_c20220331_zqvXsnLndnsa" title="Performance obligations::XDX::1%2C394%2C694"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0469"&gt;1,394,693&lt;/span&gt;&lt;/span&gt; and will be recognized into revenue over time as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 55%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; width: 75%"&gt;&lt;span style="font-size: 10pt"&gt;2022 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearOneMember_z6Wfpp48xAs9" style="text-align: right; width: 23%" title="2022"&gt;&lt;span style="font-size: 10pt"&gt;676,650&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_984_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearTwoMember_zEIPkzoKDi0c" style="text-align: right" title="2023"&gt;&lt;span style="font-size: 10pt"&gt;359,022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_980_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearThreeMember_zpVD35uTLAOg" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-size: 10pt"&gt;359,022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331_zPsmOVSaqBL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,394,694&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zOgXqoNX15c8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We defer and capitalize all costs associated with
the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the
healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged from third party installers
or directly identifiable labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line
basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying consolidated
statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--CapitalizedContractCostTableTextBlock_zqSBIh3hvcp5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;span id="xdx_8B9_zxbNPhtvTsI9"&gt;The
table below details the activity in these deferred installation costs during the periods ended March 31, 2022 and 2021, included in
other assets in the accompanying unaudited consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20220101__20220331_z0c2N25qmXLh" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210331_zsRKBDe8q7i3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedContractCostGross_iS_zs7hbUQa1kGc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;68,901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,002&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AdditionsToDeferredCosts_zeykMzLvs1nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0484"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--TransferToExpense_iN_di_z8GcGKMJ8pmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CapitalizedContractCostGross_iE_zP4dOkMftfb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,830&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;44,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zLci1VQ12fsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Significant Judgements When Applying Topic 606&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contracts with our customers are typically structured
similarly and include various combinations of our products, software solutions, and related services. Determining whether the various
contract promises are considered distinct performance obligations that should be accounted for separately versus together may require
significant judgment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract transaction price is allocated to distinct
performance obligations using estimated standalone selling price. We determine standalone selling price maximizing observable inputs such
as standalone sales, competitor standalone sales, or substantive renewal prices charged to customers when they exist. In instances where
standalone selling price is not observable, we utilize an estimate of standalone selling price. Such estimates are derived from various
methods that include cost plus margin, and historical pricing practices. Judgment may be required to determine standalone selling prices
for each performance obligation and whether it depicts the amount we expect to receive in exchange for the related good or service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract modifications occur when we and our customers
agree to modify existing customer contracts to change the scope or price (or both) of the contract or when a customer terminates some,
or all, of the existing services provided by us. When a contract modification occurs, it requires us to exercise judgment to determine
if the modification should be accounted for as a separate contract, the termination of the original contract and creation of a new contract,
a cumulative catch-up adjustment to the original contract, or a combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contracts with our customers include a limited warranty
on our products covering materials, workmanship, or design for the duration of contract. We do not offer paid additional extended or lifetime
warranty packages. We determined the limited warranty in our contract is not a distinct performance obligation. We do not believe our
estimates of warranty costs to be significant to our determination of revenue recognition and, therefore, did not reserve for warranty
costs.&lt;/p&gt;

&lt;p id="xdx_85A_zZd1sjoeZHge" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zNUFY0qzerrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zzKeUnCUpKRg"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has an operating lease primarily consisting
of office space with a remaining lease term of 41 months. At the lease commencement date, an operating lease liability and related operating
lease asset are recognized. The operating lease liabilities are calculated using the present value of lease payments. The discount rate
used is either the rate implicit in the lease, when known, or our estimated incremental borrowing rate. Operating lease assets are valued
based on the initial operating lease liabilities plus any prepaid rent and direct costs from executing the leases.&lt;/p&gt;

&lt;p id="xdx_859_zpRB0EXZFkR" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zlL8JgrLWId7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zvrIdmFxdOuf"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;We calculate earnings per share (&#x201c;EPS&#x201d;) in accordance
with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted
average number of common shares outstanding during the period. Diluted EPS is computed based on the weighted average number of common
shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential
dilutive common shares consist of stock options, warrants to purchase our Common Stock (the &#x201c;Warrants&#x201d;) and convertible debt.
Potential common shares totaling approximately &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20220331_zOEhsqEuzH87" title="Anti-dilutive common share equivalents excluded from EPS calculation"&gt;178,543,025&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20210331_zvdlFJ8TpeTl" title="Anti-dilutive common share equivalents excluded from EPS calculation"&gt;211,000,000&lt;/span&gt; at March 31, 2022 and 2021, respectively, have been excluded
from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.&lt;/p&gt;

&lt;p id="xdx_85C_zeBQL9sZnXHi" style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zcZ1yyP0eIe1" style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reclassification&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;Certain amounts reported in prior years in the financial statements have been reclassified to conform to the current year's presentation.&lt;/p&gt;

&lt;p id="xdx_852_zvMBoGhV8j54" style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

</us-gaap:BasisOfPresentationAndSignificantAccountingPoliciesTextBlock>
    <us-gaap:BasisOfAccountingPolicyPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_842_eus-gaap--BasisOfAccountingPolicyPolicyTextBlock_zk9Tx8ii9Id1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86E_zD6cd6L2Y1Gd"&gt;Interim Financial Statements&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The accompanying unaudited interim condensed
consolidated financial statements of CareView Communications, Inc. ("CareView", the "Company", "we",
"us" or "our") have been prepared in accordance with generally accepted accounting principles in the United States
of America ("GAAP") for interim financial information and with the instructions to Form 10-Q. Accordingly, they do not
include all of the information and footnotes required by GAAP for complete financial statements. In the opinion of management, such
financial statements include all adjustments (consisting solely of normal recurring adjustments) necessary for the fair statement of
the financial information included herein in accordance with GAAP and the rules and regulations of the Securities and Exchange
Commission (the "SEC"). The balance sheet at December 31, 2021 has been derived from the audited consolidated financial
statements at that date but does not include all of the information and footnotes required by GAAP for complete financial
statements. The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions
that affect the reported amounts of assets and liabilities and the disclosure of contingent assets and liabilities at the date of
the financial statements and the reported amounts of revenue and expenses during the period. Actual results could differ from those
estimates. Results of operations for interim periods are not necessarily indicative of results for the full year. The accompanying
unaudited condensed consolidated financial statements should be read in conjunction with the audited consolidated financial
statements and related notes included in our Annual Report on Form 10-K for the year ended December 31, 2021 as filed with the SEC
on March 31, 2022.&lt;/p&gt;

</us-gaap:BasisOfAccountingPolicyPolicyTextBlock>
    <us-gaap:RevenueRecognitionPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84B_eus-gaap--RevenueRecognitionPolicyTextBlock_zbQME6RX58T3" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86A_zOdaI8yDg916"&gt;Revenue Recognition&lt;/span&gt; &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We recognize revenue in accordance with Accounting
Standards Codification (&#x201c;ASC&#x201d;) Topic 606 (&#x201c;ASC 606&#x201d;). For our subscription service contracts, we have employed
the practical expedient discussed in ASC 606-10-55-18 related to invoicing as we have the right to consideration from our customers in
the amount that corresponds directly with the value to the customer of our performance completed to date and therefore, we recognize revenue
upon invoicing as further discussed below.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;br/&gt;
In accordance with ASC 606, revenue is recognized when a customer obtains control of promised goods or services. The amount of revenue
recognized reflects the consideration to which we expect to be entitled to receive in exchange for these goods or services. The provisions
of ASC 606 include a five-step process by which we determine revenue recognition, depicting the transfer of goods or services to customers
in amounts reflecting the payment to which we expect to be entitled in exchange for those goods or services. ASC 606 requires us to apply
the following steps: (1) identify the contract with the customer; (2) identify the performance obligations in the contract; (3) determine
the transaction price; (4) allocate the transaction price to the performance obligations in the contract; and (5) recognize revenue when,
or as, we satisfy the performance obligation. For those customers for which we are required to collect sales taxes, we record such sales
taxes on a net basis which has no effect on the amount of revenue or expenses recognized as the sales taxes are a flow through to the
taxing authority.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We enter into contracts with customers that may provide
multiple combinations of our products, software solutions, and other related services, which are generally capable of being distinct and
accounted for as separate performance obligations. Performance obligations that are not distinct at contract inception are combined.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Customer contract fulfillment typically involves
multiple procurement promises, which may include various equipment, software subscription, project-related installation and training
services, and support. We allocate the transaction price to each performance obligation based on estimated relative standalone
selling price. Revenue is then recognized for each performance obligation upon transferring control of the hardware, software, and
services to the customer and in an amount that reflects the consideration we expect to receive and the estimated benefit the
customer receives over the term of the contract.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;
&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Generally, we recognize revenue under each of our
performance obligations as follows:&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Subscription services &#x2013;
We recognize subscription revenues monthly over the contracted license period.&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Equipment packages &#x2013; We
recognize equipment revenues when control of the devices has been transferred to the client (&#x201c;point in time&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; margin-top: 0; margin-bottom: 0"&gt;&lt;tr style="vertical-align: top"&gt;
&lt;td style="width: 0.25in"/&gt;&lt;td style="width: 0.25in"&gt;&lt;span style="font-family: Symbol; font-size: 10pt"&gt;&#xb7;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Software bundle and related
services related to sales-based contracts &#x2013; We recognize our software subscription, installation, training, and other services on
a straight-line basis over the estimated contracted license period (&#x201c;over time&#x201d;).&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Disaggregation of Revenue&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zeXAVAydEsue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zJUszMfrftol"&gt;The following presents gross revenues disaggregated
by our business models:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Sales-based contract revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&#160;&#160;Equipment package, net (point in time)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedEquipmentPackageRevenueMember_zDsF0CWqcmM1" style="width: 12%; text-align: right" title="Gross revenue"&gt;817,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedEquipmentPackageRevenueMember_z2IpSdHV1pPi" style="width: 12%; text-align: right" title="Gross revenue"&gt;979,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Software bundle (over time)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedSoftwareBundleRevenueMember_zKyVxdvgYQrk" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;194,154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedSoftwareBundleRevenueMember_zeXVQrkdtVDb" style="border-bottom: Black 1pt solid; text-align: right"&gt;34,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Total sales-based contract revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zE8RhGSuNToc" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;1,011,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zQESAmze0C0g" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,014,840&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Subscription-based lease revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SubscriptionBasedLeaseRevenueMember_zD47GtK2O5mk" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;1,307,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SubscriptionBasedLeaseRevenueMember_z1vBzb1ORKx3" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,350,043&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;Gross revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20220101__20220331_zyZVE4QT08oe" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross revenue"&gt;2,319,029&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20210101__20210331_z5jGtq3t2spe" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,364,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A2_zgtqffh3Qsui" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;i&gt;&lt;span style="text-decoration: underline"&gt;Contract Liabilities&lt;/span&gt;&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our subscription-based contracts payment arrangements
are required to be paid monthly which are recognized into revenue when received. Some customers choose to pay their subscription fee in
advance. Customer payments received in advance of satisfaction of the related performance obligations are deferred as contract liabilities.
These amounts are recorded as &#x201c;deferred revenue&#x201d; in our condensed consolidated balance sheet and recognized into revenues
over time.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Our sales-based contract payment arrangements with
our customers typically include an initial equipment payment due upon signing of the contract and subsequent payments when certain performance
obligations are completed. Customer payments received in advance of satisfaction of related performance obligations are deferred as contract
liabilities. These amounts are recorded as &#x201c;deferred revenue&#x201d; in our condensed consolidated balance sheet and recognized
into revenues as either a point in time or over time.&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zo6CXmIXJWX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2022 and 2021,
a total of $&lt;span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_z1pLhstRMdIh" title="Contract liability recognized as revenue"&gt;83,194&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_znUoFMlJa9y2" title="Contract liability recognized as revenue"&gt;67,165&lt;/span&gt; respectively, of the beginning balance of the subscription-based contract liability was recognized as revenue.
&lt;span id="xdx_8B5_z0WhjzXY5nt8"&gt;The table below details the subscription-based contract liability activity&lt;/span&gt; during the three months ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zuTM89dRUzjj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zLEi32Ztmerc" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_ztuZW3hI9ioh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;231,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;238,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityAdditions_zD1uxo7o2pFg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0442"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_z0o6rrztC283" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(83,194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(78,819&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ContractWithCustomerLiability_iE_zusWYl9Hl8x4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;147,946&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;229,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2022 and 2021,
a total of $&lt;span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pp0p0_c20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zpQCbdlnWdRe" title="Contract liability recognized as revenue"&gt;490,374&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zollTy6K9Qzg" title="Contract liability recognized as revenue"&gt;166,880&lt;/span&gt;, respectively, of the beginning balance of the sales-based contract liability was recognized as revenue.
The table below details the sales-based contract liability activity during the three months ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zzB6eY3Ypgaa" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zZ9bNU2jr7V1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zeYiyepSgPs4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;752,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;226,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityAdditions_zPSF0RTp8W0i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;939,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zvDcPjKuTD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,011,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,014,841&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ContractWithCustomerLiability_iE_zimA1aV61Q3l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,246,747&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;151,048&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zFYyu6TBnIV4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89B_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_zQFGd1DbzISa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8B1_z82amqUx9yT5"&gt;As of March 31, 2022, the aggregate amount of deferred
revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied or partially
satisfied&lt;/span&gt; is approximately $&lt;span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_dxL_c20220331_zqvXsnLndnsa" title="Performance obligations::XDX::1%2C394%2C694"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0469"&gt;1,394,693&lt;/span&gt;&lt;/span&gt; and will be recognized into revenue over time as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 55%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; width: 75%"&gt;&lt;span style="font-size: 10pt"&gt;2022 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearOneMember_z6Wfpp48xAs9" style="text-align: right; width: 23%" title="2022"&gt;&lt;span style="font-size: 10pt"&gt;676,650&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_984_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearTwoMember_zEIPkzoKDi0c" style="text-align: right" title="2023"&gt;&lt;span style="font-size: 10pt"&gt;359,022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_980_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearThreeMember_zpVD35uTLAOg" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-size: 10pt"&gt;359,022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331_zPsmOVSaqBL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,394,694&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8AE_zOgXqoNX15c8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We defer and capitalize all costs associated with
the installation of the CareView System into a healthcare facility until the CareView System is fully operational and accepted by the
healthcare facility. Installation costs are specifically identifiable based on the amounts we are charged from third party installers
or directly identifiable labor hours incurred for each installation. Upon acceptance, the associated costs are expensed on a straight-line
basis over the life of the contract with the healthcare facility. These costs are included in network operations on the accompanying consolidated
statements of operations.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--CapitalizedContractCostTableTextBlock_zqSBIh3hvcp5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;span id="xdx_8B9_zxbNPhtvTsI9"&gt;The
table below details the activity in these deferred installation costs during the periods ended March 31, 2022 and 2021, included in
other assets in the accompanying unaudited consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20220101__20220331_z0c2N25qmXLh" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210331_zsRKBDe8q7i3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedContractCostGross_iS_zs7hbUQa1kGc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;68,901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,002&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AdditionsToDeferredCosts_zeykMzLvs1nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0484"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--TransferToExpense_iN_di_z8GcGKMJ8pmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CapitalizedContractCostGross_iE_zP4dOkMftfb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,830&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;44,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zLci1VQ12fsl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;i&gt;Significant Judgements When Applying Topic 606&lt;/i&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contracts with our customers are typically structured
similarly and include various combinations of our products, software solutions, and related services. Determining whether the various
contract promises are considered distinct performance obligations that should be accounted for separately versus together may require
significant judgment.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract transaction price is allocated to distinct
performance obligations using estimated standalone selling price. We determine standalone selling price maximizing observable inputs such
as standalone sales, competitor standalone sales, or substantive renewal prices charged to customers when they exist. In instances where
standalone selling price is not observable, we utilize an estimate of standalone selling price. Such estimates are derived from various
methods that include cost plus margin, and historical pricing practices. Judgment may be required to determine standalone selling prices
for each performance obligation and whether it depicts the amount we expect to receive in exchange for the related good or service.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contract modifications occur when we and our customers
agree to modify existing customer contracts to change the scope or price (or both) of the contract or when a customer terminates some,
or all, of the existing services provided by us. When a contract modification occurs, it requires us to exercise judgment to determine
if the modification should be accounted for as a separate contract, the termination of the original contract and creation of a new contract,
a cumulative catch-up adjustment to the original contract, or a combination.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Contracts with our customers include a limited warranty
on our products covering materials, workmanship, or design for the duration of contract. We do not offer paid additional extended or lifetime
warranty packages. We determined the limited warranty in our contract is not a distinct performance obligation. We do not believe our
estimates of warranty costs to be significant to our determination of revenue recognition and, therefore, did not reserve for warranty
costs.&lt;/p&gt;

</us-gaap:RevenueRecognitionPolicyTextBlock>
    <us-gaap:DisaggregationOfRevenueTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89D_eus-gaap--DisaggregationOfRevenueTableTextBlock_zeXAVAydEsue" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B3_zJUszMfrftol"&gt;The following presents gross revenues disaggregated
by our business models:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 85%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;Sales-based contract revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;&#160;&#160;Equipment package, net (point in time)&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedEquipmentPackageRevenueMember_zDsF0CWqcmM1" style="width: 12%; text-align: right" title="Gross revenue"&gt;817,012&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedEquipmentPackageRevenueMember_z2IpSdHV1pPi" style="width: 12%; text-align: right" title="Gross revenue"&gt;979,977&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Software bundle (over time)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedSoftwareBundleRevenueMember_zKyVxdvgYQrk" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;194,154&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedSoftwareBundleRevenueMember_zeXVQrkdtVDb" style="border-bottom: Black 1pt solid; text-align: right"&gt;34,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;&#160;&#160;Total sales-based contract revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zE8RhGSuNToc" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;1,011,166&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SalesBasedContractRevenueMember_zQESAmze0C0g" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,014,840&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;Subscription-based lease revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20220101__20220331__srt--ProductOrServiceAxis__custom--SubscriptionBasedLeaseRevenueMember_zD47GtK2O5mk" style="border-bottom: Black 1pt solid; text-align: right" title="Gross revenue"&gt;1,307,863&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_c20210101__20210331__srt--ProductOrServiceAxis__custom--SubscriptionBasedLeaseRevenueMember_z1vBzb1ORKx3" style="border-bottom: Black 1pt solid; text-align: right"&gt;1,350,043&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;Gross revenue&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20220101__20220331_zyZVE4QT08oe" style="border-bottom: Black 2.5pt double; text-align: right" title="Gross revenue"&gt;2,319,029&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--RevenueFromContractWithCustomerExcludingAssessedTax_maRev_c20210101__20210331_z5jGtq3t2spe" style="border-bottom: Black 2.5pt double; text-align: right"&gt;2,364,883&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:DisaggregationOfRevenueTableTextBlock>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SalesBasedEquipmentPackageRevenueMember"
      decimals="0"
      unitRef="USD">817012</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SalesBasedEquipmentPackageRevenueMember"
      decimals="0"
      unitRef="USD">979977</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SalesBasedSoftwareBundleRevenueMember"
      decimals="0"
      unitRef="USD">194154</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SalesBasedSoftwareBundleRevenueMember"
      decimals="0"
      unitRef="USD">34863</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SalesBasedContractRevenueMember"
      decimals="0"
      unitRef="USD">1011166</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SalesBasedContractRevenueMember"
      decimals="0"
      unitRef="USD">1014840</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-012022-03-31_custom_SubscriptionBasedLeaseRevenueMember"
      decimals="0"
      unitRef="USD">1307863</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31_custom_SubscriptionBasedLeaseRevenueMember"
      decimals="0"
      unitRef="USD">1350043</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">2319029</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">2364883</us-gaap:RevenueFromContractWithCustomerExcludingAssessedTax>
    <us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89D_eus-gaap--ContractWithCustomerAssetAndLiabilityTableTextBlock_zo6CXmIXJWX9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2022 and 2021,
a total of $&lt;span id="xdx_90B_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_z1pLhstRMdIh" title="Contract liability recognized as revenue"&gt;83,194&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_znUoFMlJa9y2" title="Contract liability recognized as revenue"&gt;67,165&lt;/span&gt; respectively, of the beginning balance of the subscription-based contract liability was recognized as revenue.
&lt;span id="xdx_8B5_z0WhjzXY5nt8"&gt;The table below details the subscription-based contract liability activity&lt;/span&gt; during the three months ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_493_20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zuTM89dRUzjj" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SubscriptionBasisContractMember_zLEi32Ztmerc" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_ztuZW3hI9ioh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;231,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;238,263&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityAdditions_zD1uxo7o2pFg" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0442"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;69,923&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_z0o6rrztC283" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(83,194&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(78,819&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ContractWithCustomerLiability_iE_zusWYl9Hl8x4" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;147,946&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;229,367&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2022 and 2021,
a total of $&lt;span id="xdx_904_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_pp0p0_c20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zpQCbdlnWdRe" title="Contract liability recognized as revenue"&gt;490,374&lt;/span&gt; and $&lt;span id="xdx_90F_eus-gaap--ContractWithCustomerLiabilityRevenueRecognized_c20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zollTy6K9Qzg" title="Contract liability recognized as revenue"&gt;166,880&lt;/span&gt;, respectively, of the beginning balance of the sales-based contract liability was recognized as revenue.
The table below details the sales-based contract liability activity during the three months ended March 31, 2022 and 2021.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_498_20220101__20220331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zzB6eY3Ypgaa" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_492_20210101__20210331__us-gaap--ContractWithCustomerBasisOfPricingAxis__custom--SalesBasisContractMember_zZ9bNU2jr7V1" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2022&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;2021&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--ContractWithCustomerLiability_iS_zeYiyepSgPs4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;752,526&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;226,861&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_ecustom--ContractWithCustomerLiabilityAdditions_zPSF0RTp8W0i" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,505,386&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;939,028&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_ecustom--ContractWithCustomerLiabilityTransferToRevenue_iN_di_zvDcPjKuTD9f" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to revenue&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,011,165&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(1,014,841&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--ContractWithCustomerLiability_iE_zimA1aV61Q3l" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,246,747&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;151,048&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ContractWithCustomerAssetAndLiabilityTableTextBlock>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2022-01-012022-03-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">83194</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2021-01-012021-03-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">67165</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2021-12-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">231140</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2020-12-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">238263</us-gaap:ContractWithCustomerLiability>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2021-01-012021-03-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">69923</crvw:ContractWithCustomerLiabilityAdditions>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2022-01-012022-03-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">83194</crvw:ContractWithCustomerLiabilityTransferToRevenue>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2021-01-012021-03-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">78819</crvw:ContractWithCustomerLiabilityTransferToRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2022-03-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">147946</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2021-03-31_custom_SubscriptionBasisContractMember"
      decimals="0"
      unitRef="USD">229367</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2022-01-012022-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">490374</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiabilityRevenueRecognized
      contextRef="From2021-01-012021-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">166880</us-gaap:ContractWithCustomerLiabilityRevenueRecognized>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2021-12-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">752526</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2020-12-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">226861</us-gaap:ContractWithCustomerLiability>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2022-01-012022-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">1505386</crvw:ContractWithCustomerLiabilityAdditions>
    <crvw:ContractWithCustomerLiabilityAdditions
      contextRef="From2021-01-012021-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">939028</crvw:ContractWithCustomerLiabilityAdditions>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2022-01-012022-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">1011165</crvw:ContractWithCustomerLiabilityTransferToRevenue>
    <crvw:ContractWithCustomerLiabilityTransferToRevenue
      contextRef="From2021-01-012021-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">1014841</crvw:ContractWithCustomerLiabilityTransferToRevenue>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2022-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">1246747</us-gaap:ContractWithCustomerLiability>
    <us-gaap:ContractWithCustomerLiability
      contextRef="AsOf2021-03-31_custom_SalesBasisContractMember"
      decimals="0"
      unitRef="USD">151048</us-gaap:ContractWithCustomerLiability>
    <us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89B_eus-gaap--RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock_zQFGd1DbzISa" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span&gt;&lt;span id="xdx_8B1_z82amqUx9yT5"&gt;As of March 31, 2022, the aggregate amount of deferred
revenue from subscription-based contracts and sales-based contracts allocated to performance obligations that are unsatisfied or partially
satisfied&lt;/span&gt; is approximately $&lt;span id="xdx_903_eus-gaap--RevenueRemainingPerformanceObligation_iI_dxL_c20220331_zqvXsnLndnsa" title="Performance obligations::XDX::1%2C394%2C694"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0469"&gt;1,394,693&lt;/span&gt;&lt;/span&gt; and will be recognized into revenue over time as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; width: 55%; border-collapse: collapse; margin-right: auto"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Years Ending December 31,&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;span style="font-size: 10pt"&gt;&lt;b&gt;Amount&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; width: 75%"&gt;&lt;span style="font-size: 10pt"&gt;2022 &lt;/span&gt;&lt;/td&gt;
    &lt;td style="text-align: right; width: 2%"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98F_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearOneMember_z6Wfpp48xAs9" style="text-align: right; width: 23%" title="2022"&gt;&lt;span style="font-size: 10pt"&gt;676,650&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;2023&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_984_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearTwoMember_zEIPkzoKDi0c" style="text-align: right" title="2023"&gt;&lt;span style="font-size: 10pt"&gt;359,022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Thereafter&lt;/span&gt;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_980_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331__custom--PerformanceDateAxis__custom--YearThreeMember_zpVD35uTLAOg" style="border-bottom: Black 1pt solid; text-align: right" title="Thereafter"&gt;&lt;span style="font-size: 10pt"&gt;359,022&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;&lt;span style="font-size: 10pt"&gt;$&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98A_eus-gaap--RevenueRemainingPerformanceObligation_iI_c20220331_zPsmOVSaqBL6" style="border-bottom: Black 2.5pt double; text-align: right" title="Revenue"&gt;&lt;span style="font-size: 10pt"&gt;1,394,694&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</us-gaap:RevenueRemainingPerformanceObligationExpectedTimingOfSatisfactionTableTextBlock>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2022-03-31_custom_YearOneMember"
      decimals="0"
      unitRef="USD">676650</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2022-03-31_custom_YearTwoMember"
      decimals="0"
      unitRef="USD">359022</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation
      contextRef="AsOf2022-03-31_custom_YearThreeMember"
      decimals="0"
      unitRef="USD">359022</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:RevenueRemainingPerformanceObligation contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1394694</us-gaap:RevenueRemainingPerformanceObligation>
    <us-gaap:CapitalizedContractCostTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_895_eus-gaap--CapitalizedContractCostTableTextBlock_zqSBIh3hvcp5" style="font: 10pt Times New Roman, Times, Serif; margin-right: 0; margin-left: 0"&gt;&lt;span id="xdx_8B9_zxbNPhtvTsI9"&gt;The
table below details the activity in these deferred installation costs during the periods ended March 31, 2022 and 2021, included in
other assets in the accompanying unaudited consolidated balance sheet.&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td id="xdx_496_20220101__20220331_z0c2N25qmXLh" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;
    &lt;td colspan="2" id="xdx_494_20210101__20210331_zsRKBDe8q7i3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="7" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31,&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_404_eus-gaap--CapitalizedContractCostGross_iS_zs7hbUQa1kGc" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify"&gt;Balance, beginning of period&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;68,901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;54,002&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AdditionsToDeferredCosts_zeykMzLvs1nb" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&#160;&#160;Additions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0484"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0485"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_ecustom--TransferToExpense_iN_di_z8GcGKMJ8pmf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt"&gt;&#160;&#160;Transfer to expense&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(12,071&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;(9,442&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--CapitalizedContractCostGross_iE_zP4dOkMftfb1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 2.5pt"&gt;Balance, end of period&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;56,830&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;44,560&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:CapitalizedContractCostTableTextBlock>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">68901</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2020-12-31" decimals="0" unitRef="USD">54002</us-gaap:CapitalizedContractCostGross>
    <crvw:TransferToExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">12071</crvw:TransferToExpense>
    <crvw:TransferToExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">9442</crvw:TransferToExpense>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">56830</us-gaap:CapitalizedContractCostGross>
    <us-gaap:CapitalizedContractCostGross contextRef="AsOf2021-03-31" decimals="0" unitRef="USD">44560</us-gaap:CapitalizedContractCostGross>
    <us-gaap:LesseeLeasesPolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_84F_eus-gaap--LesseeLeasesPolicyTextBlock_zNUFY0qzerrb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_861_zzKeUnCUpKRg"&gt;Leases&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has an operating lease primarily consisting
of office space with a remaining lease term of 41 months. At the lease commencement date, an operating lease liability and related operating
lease asset are recognized. The operating lease liabilities are calculated using the present value of lease payments. The discount rate
used is either the rate implicit in the lease, when known, or our estimated incremental borrowing rate. Operating lease assets are valued
based on the initial operating lease liabilities plus any prepaid rent and direct costs from executing the leases.&lt;/p&gt;

</us-gaap:LesseeLeasesPolicyTextBlock>
    <us-gaap:EarningsPerSharePolicyTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_849_eus-gaap--EarningsPerSharePolicyTextBlock_zlL8JgrLWId7" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;&lt;span id="xdx_86D_zvrIdmFxdOuf"&gt;Earnings Per Share&lt;/span&gt;&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;We calculate earnings per share (&#x201c;EPS&#x201d;) in accordance
with GAAP, which requires the computation and disclosure of two EPS amounts, basic and diluted. Basic EPS is computed based on the weighted
average number of common shares outstanding during the period. Diluted EPS is computed based on the weighted average number of common
shares outstanding plus all potentially dilutive common shares outstanding during the period under the treasury stock method. Such potential
dilutive common shares consist of stock options, warrants to purchase our Common Stock (the &#x201c;Warrants&#x201d;) and convertible debt.
Potential common shares totaling approximately &lt;span id="xdx_900_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20220101__20220331_zOEhsqEuzH87" title="Anti-dilutive common share equivalents excluded from EPS calculation"&gt;178,543,025&lt;/span&gt; and &lt;span id="xdx_90B_eus-gaap--AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_pid_uShares_c20210101__20210331_zvdlFJ8TpeTl" title="Anti-dilutive common share equivalents excluded from EPS calculation"&gt;211,000,000&lt;/span&gt; at March 31, 2022 and 2021, respectively, have been excluded
from the diluted earnings per share calculation as they are anti-dilutive due to our reported net loss.&lt;/p&gt;

</us-gaap:EarningsPerSharePolicyTextBlock>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">178543025</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
      contextRef="From2021-01-012021-03-31"
      decimals="INF"
      unitRef="Shares">211000000</us-gaap:AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount>
    <us-gaap:PriorPeriodReclassificationAdjustmentDescription contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_843_eus-gaap--PriorPeriodReclassificationAdjustmentDescription_zcZ1yyP0eIe1" style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Reclassification&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;Certain amounts reported in prior years in the financial statements have been reclassified to conform to the current year's presentation.&lt;/p&gt;

</us-gaap:PriorPeriodReclassificationAdjustmentDescription>
    <crvw:LiquidityAndManagmentsPlanTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_800_ecustom--LiquidityAndManagmentsPlanTextBlock_z87qg6iC79I6" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 2 &#x2013; &lt;span id="xdx_826_zH7PfGPD5T5h"&gt;GOING CONCERN, LIQUIDITY AND
MANAGEMENT'S PLAN&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Accounting standards require management to evaluate
whether the Company can continue as a going concern for a period of one year after the date of the filing of this Form 10-Q (&#x201c;evaluation
period&#x201d;). In evaluating the Company&#x2019;s ability to continue as a going concern, Management considers the conditions and events
that raise substantial doubt about the Company&#x2019;s ability to continue as a going concern for a period of twelve months after the
Company issues its financial statements. For the three months ended March 31, 2022, Management considers the Company&#x2019;s current financial
condition and liquidity sources, including current funds available, forecasted future cash flows, and the Company&#x2019;s conditional
and unconditional obligations due within 12 months of the date these financial statements are issued.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company is subject to risks like those of healthcare
technology companies whereby revenues are generated based on both sales-based and subscription-based models, which assume dependence on
key individuals, uncertainty of product development, generation of revenues, positive cash flow, dependence on outside sources of capital,
risks associated with research, development, and successful testing of its products, successful protection of intellectual property, ability
to maintain and grow its customer base, and susceptibility to infringement on the proprietary rights of others. The attainment of profitable
operations is dependent on future events, including obtaining adequate financing to fulfill the Company&#x2019;s growth and operating activities
and generating a level of revenues adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has experienced net losses and
significant cash outflows from cash used in operating activities over the past years. As of and for the three months ended March 31,
2022, the Company had an accumulated deficit of approximately $&lt;span id="xdx_902_eus-gaap--RetainedEarningsAccumulatedDeficit_iI_dxL_c20220331_zF1Gy1dmxQk4" title="Accumulated deficit::XDX::-200235054"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0505"&gt;200,200,000&lt;/span&gt;&lt;/span&gt;,
loss from operations of approximately $&lt;span id="xdx_900_eus-gaap--OperatingIncomeLoss_dxL_c20220101__20220331_zN6ASPw3Pcwg" title="Operating income / (loss)::XDX::-323224"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0507"&gt;323,000&lt;/span&gt;&lt;/span&gt;, net
cash provided by operating activities of $&lt;span id="xdx_906_eus-gaap--NetCashProvidedByUsedInOperatingActivities_c20220101__20220331_zb0NcPqKebrb" title="Net cash provided by operating activities"&gt;178,896&lt;/span&gt; and
an ending cash balance of $&lt;span id="xdx_902_eus-gaap--CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_iI_c20220331_zC2JSNZM1Z15" title="Cash balance"&gt;764,707&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 31, 2022, the Company had cash and a
working capital deficit of $&lt;span id="xdx_906_ecustom--WorkingCapitalDeficit_iI_c20220331_zwZ8wmqE24V4"&gt;31,827,363 &lt;/span&gt;consisting
primarily of notes payables. Management has evaluated the significance of the conditions described above in relation to the
Company&#x2019;s ability to meet its obligations and concluded that, without additional funding, the Company will not have sufficient
funds to meet its obligations within one year from the date the unaudited condensed consolidated financial statements were issued.
While management will look to continue funding operations by increased sales volumes and raising additional capital from sources
such as sales of its debt or equity securities or loans to meet operating cash requirements, there is no assurance that
management&#x2019;s plans will be successful.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;As of March 8, 2022, the company extended HealthCor
2011 and 2012 notes through April 20, 2023 by entering Allonge No.4, and we issued warrants to purchase an aggregate of &lt;span id="xdx_905_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_uShares_c20220308__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorAllongeNo4WarrantsMember_zvz2aLxilYKd" title="Number of warrants issued"&gt;3,000,000&lt;/span&gt; shares
of our Common Stock at an exercise price per share equal to $&lt;span id="xdx_900_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20220308__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorAllongeNo4WarrantsMember_zhqOI79I72yc" title="Warrant exercise price (in dollars per share)"&gt;0.09&lt;/span&gt; per share.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Arial, Helvetica, Sans-Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Management continues to monitor the immediate
and future cash flows needs of the company in a variety of ways which include forecasted net cash flows from operations, capital
expenditure control, new inventory orders, debt modifications, increases sales outreach, streamlining and controlling general and
administrative costs, competitive industry pricing, sale of equities, debt conversions, new product or services offerings, and new
business partnerships.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company&#x2019;s net losses, cash outflows,
and working capital deficit raise substantial doubt about the Company&#x2019;s ability to continue as a going concern. The
accompanying unaudited condensed consolidated financial statements have been prepared assuming that the Company will continue as a
going concern. This basis of accounting contemplates the recovery of the Company&#x2019;s assets and the satisfaction of liabilities
in the normal course of business. A successful transition to attaining profitable operations is dependent upon achieving a level of
positive cash flows adequate to support the Company&#x2019;s cost structure.&lt;/p&gt;

</crvw:LiquidityAndManagmentsPlanTextBlock>
    <us-gaap:NetCashProvidedByUsedInOperatingActivities
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">178896</us-gaap:NetCashProvidedByUsedInOperatingActivities>
    <us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">764707</us-gaap:CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents>
    <crvw:WorkingCapitalDeficit contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">31827363</crvw:WorkingCapitalDeficit>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2022-03-08_custom_HealthCorAllongeNo4WarrantsMember"
      decimals="INF"
      unitRef="Shares">3000000</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-08_custom_HealthCorAllongeNo4WarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:StockholdersEquityNoteDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80B_eus-gaap--StockholdersEquityNoteDisclosureTextBlock_zZ055tf9YkHl" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 3 &#x2013; &lt;span id="xdx_82E_znK2OZ2DkmVl"&gt;STOCKHOLDERS&#x2019; EQUITY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Warrants to Purchase Common Stock of the Company&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;We use the Black-Scholes-Merton option pricing model
(&#x201c;Black-Scholes Model&#x201d;) to determine the fair value of Warrants (except Warrants issued to HealthCor in 2011 (the &#x201c;2011
HealthCor Warrants&#x201d;) as discussed in NOTE 11 and the warrants issued in connection with a private placement completed in April 2013
(&#x201c;Private Placement Warrants&#x201d;). The Black-Scholes Model requires the use of several assumptions including volatility of the
stock price, the weighted average risk-free interest rate, and the weighted average term of the Warrant.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The risk-free interest rate assumption is based upon
observed interest rates on zero coupon U.S. Treasury bonds whose maturity period is appropriate for the term of the Warrants and is calculated
by using the average daily historical stock prices through the day preceding the grant date. Estimated volatility is a measure of the
amount by which our stock price is expected to fluctuate each year during the expected life of the award. Our estimated volatility is
an average of the historical volatility of our stock prices (and that of peer entities whose stock prices were publicly available) over
a period equal to the expected life of the awards. Where appropriate we used the historical volatility of peer entities due to the lack
of sufficient historical data of our stock price during 2007- 2009. On April 20, 2021, we issued &lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_uShares_c20210420__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorPartnersWarrantsMember_z3ODkaEdzpac" title="Number of warrants issued"&gt;931,600&lt;/span&gt; and &lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights_iI_pid_uShares_c20210420__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorHybridWarrantsMember_zzmgdFJ0rTVf" title="Number of warrants issued"&gt;1,068,400&lt;/span&gt; warrants to purchase
our Common Stock at an exercise price of $&lt;span id="xdx_90C_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20210420__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorWarrantsMember_zIl6DPG6RqJk" title="Warrant exercise price (in dollars per share)"&gt;0.23&lt;/span&gt; per share to HealthCor Partners and HealthCor Hybrid, respectively. See NOTE 11.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zd0e5DW5oPp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_za5Q2m531hUl"&gt;A summary of our Warrants activity and related information
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of &lt;br/&gt;
    Shares Under &lt;br/&gt;
    Warrant&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Range of
    &lt;br/&gt;Warrant Price &lt;br/&gt;Per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 16%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOqbMul1esLa" style="width: 16%; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, beginning"&gt;18,050,458&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zpveRW9yxvqg" title="Warrant price, beginning"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAa3zFDI1DG3" title="Warrant price, beginning"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--WeightedAverageExercisePriceWarrant_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zunWe6uPbnnk" style="width: 15%; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning"&gt;0.74&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightsContractualLifeBeginning_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zU4gzYTA2A91" title="Warrant term, beginning"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightsWarrantsGranted_pid_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zwebvwIBkO35" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrants granted"&gt;3,000,000&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--RangeOfWarrantPricePerShareWarrantGranted_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zWq87fm9fDj5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant price granted"&gt;0.08&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsGranted_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zqWMgZEPrc66" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;0.08&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightsContractualLifeGranted_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_za6NAiyqMXdc" title="Warrant term, granted"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zO2VUoRhmY38" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending"&gt;21,050,458&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zCGizb8pm6C3" title="Warrant price, ending"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zeSvyCXgN658" title="Warrant price, ending"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WeightedAverageExercisePriceWarrant_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOkUSA1YxGAg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending"&gt;0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRightsContractualLifeEnding_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zy1CizYqvKpi" title="Warrant term, ending"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


&lt;p id="xdx_8A9_zloyhvJj3wkb" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Options to Purchase Common Stock of the Company&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;During the three months ended March 31, 2022, &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331_zVTuuVxoP9u7" title="Options granted"&gt;141,500&lt;/span&gt;
options to purchase our Common Stock were granted having a fair value of $&lt;span id="xdx_90C_ecustom--StockGrantedDuringPeriodValueSharebasedCompensationGrossStockGrantedDuringPeriodValueSharebasedCompensationGross_uUSD_c20220101__20220331_zCx987cv400d" title="Options granted, fair value"&gt;15,280&lt;/span&gt; in which &lt;span id="xdx_909_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceOneMember_zl9I3HTzX7Ph"&gt;85,000&lt;/span&gt; options have exercise price of $&lt;span id="xdx_905_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit_pid_uUSDPShares_c20220101__20220331_zQS2lhmh30h1" title="Option exercise prices, minimum"&gt;0.1&lt;/span&gt; per
share and &lt;span id="xdx_90F_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331__us-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansByExercisePriceRangeAxis__custom--ExercisePriceTwoMember_zyOEoyepKYM8"&gt;56,500&lt;/span&gt; options have exercise price of $&lt;span id="xdx_901_eus-gaap--ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit_pid_uUSDPShares_c20220101__20220331_zHiDcDjOpLSe" title="Option exercise prices, maximum"&gt;0.12&lt;/span&gt; per share. During the three months ended March 31, 2022, no options expired or were
terminated.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKQQPcjtXjq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zWmTWeHNTJwd"&gt;A summary of our stock option activity and related
information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Number
    of Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-family: Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20220331_zO1dyYUcl7Hh" style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Beginning"&gt;40,625,477&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20220331_zlu9I7jBV2s7" style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Weighted Average Exercise Price, Beginning"&gt;0.12&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining_dtY_c20220101__20220331_zIH9vGlDM6mb" title="Stock Options Outstanding, Weighted Average Remaining Contractual Life, Beginning"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220101__20220331_zu8rvnT4xjVj" style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Aggregate Intrinsic Value, Beginning"&gt;1,283,975&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331_zw08Q48BxNb2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Granted"&gt;141,500&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Forfeited/Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Balance at March 31, 2022&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_uShares_c20220101__20220331_zx1pxUyT7JW4" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;40,766,977&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331_z8tTfQbe9551" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Weighted Average Exercise Price, Ending"&gt;0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220331_zSo3rf8Y7Yy6" title="Stock Options Outstanding, Weighted Average Remaining Contractual Life, Ending"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20220331_z9Tq4GWCKkNi" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Aggregate Intrinsic Value, Ending"&gt;807,202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;Vested and Exercisable at March 31, 2022&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20220101__20220331_z57C61VS4Di" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Vested and Exercisable"&gt;26,262,810&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331_zWNOeFYFXP56" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Vested and Exercisable, Weighted Average Exercise Price"&gt;0.16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zofcDDTBnj7c" title="Stock Options Vested and Exercisable, Weighted Average Remaining Contractual Life"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20220101__20220331_zRofFK96wKX3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Vested and Exercisable, Aggregate Intrinsic Value"&gt;805,202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AE_zJkAhHIqIphk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Share-based compensation expense for Options charged
to our operating results for the three months ended March 31, 2022 and 2021 ($&lt;span id="xdx_90D_eus-gaap--StockOptionPlanExpense_c20220101__20220331_zoCnH092Vbs3" title="Share based compensation expense"&gt;55,847&lt;/span&gt; and $&lt;span id="xdx_903_eus-gaap--StockOptionPlanExpense_c20210101__20210331_zuhKPNsf4IIf" title="Share based compensation expense"&gt;52,878&lt;/span&gt;, respectively) is based over the awards&#x2019;
vested period. The estimate of forfeitures is to be recorded at the time of grant and revised in subsequent periods if actual forfeitures
differ from the estimates. We have not included an adjustment to our stock-based compensation expense based on the nominal amount of the
historical forfeiture rate. We do, however, revise our stock-based compensation expense based on actual forfeitures during each reporting
period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;At March 31, 2022, total unrecognized estimated compensation
expense related to non-vested Options granted prior to that date was approximately $&lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions_iI_c20220331_zdM9NNNY0Fbi" title="Unrecognized estimated compensation expense"&gt;330,670&lt;/span&gt;, which is expected to be recognized over a
weighted-average period of &lt;span id="xdx_909_eus-gaap--EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1_dtY_c20220101__20220331_zhSVo0H1lfpb" title="Period for recognition of unrecognized compensation expense"&gt;1.5&lt;/span&gt; years. No tax benefit was realized due to a continued pattern of operating losses.&lt;/p&gt;

</us-gaap:StockholdersEquityNoteDisclosureTextBlock>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-04-20_custom_HealthCorPartnersWarrantsMember"
      decimals="INF"
      unitRef="Shares">931600</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
      contextRef="AsOf2021-04-20_custom_HealthCorHybridWarrantsMember"
      decimals="INF"
      unitRef="Shares">1068400</us-gaap:ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-04-20_custom_HealthCorWarrantsMember"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_897_eus-gaap--ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock_zd0e5DW5oPp8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_za5Q2m531hUl"&gt;A summary of our Warrants activity and related information
follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 95%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Number
    of &lt;br/&gt;
    Shares Under &lt;br/&gt;
    Warrant&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Range of
    &lt;br/&gt;Warrant Price &lt;br/&gt;Per Share&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center; font-family: Times New Roman, Times, Serif"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="text-align: center; font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; width: 16%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at December 31, 2021&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--ClassOfWarrantOrRightOutstanding_iS_pid_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOqbMul1esLa" style="width: 16%; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, beginning"&gt;18,050,458&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 16%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_909_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zpveRW9yxvqg" title="Warrant price, beginning"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_902_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zAa3zFDI1DG3" title="Warrant price, beginning"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_985_ecustom--WeightedAverageExercisePriceWarrant_iS_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zunWe6uPbnnk" style="width: 15%; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, beginning"&gt;0.74&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 15%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_909_ecustom--ClassOfWarrantOrRightsContractualLifeBeginning_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zU4gzYTA2A91" title="Warrant term, beginning"&gt;4.2&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Granted&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--ClassOfWarrantOrRightsWarrantsGranted_pid_uShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zwebvwIBkO35" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrants granted"&gt;3,000,000&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_ecustom--RangeOfWarrantPricePerShareWarrantGranted_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zWq87fm9fDj5" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Warrant price granted"&gt;0.08&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--WarrantsGranted_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zqWMgZEPrc66" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, granted"&gt;0.08&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_907_ecustom--ClassOfWarrantOrRightsContractualLifeGranted_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_za6NAiyqMXdc" title="Warrant term, granted"&gt;9.9&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Expired&lt;/span&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&#160;&#160;&#160;Canceled&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Balance at March 31, 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ClassOfWarrantOrRightOutstanding_iE_pid_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zO2VUoRhmY38" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Warrants outstanding, ending"&gt;21,050,458&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;span id="xdx_908_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MinimumMember_zCGizb8pm6C3" title="Warrant price, ending"&gt;0.01&lt;/span&gt;-$&lt;span id="xdx_907_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember__srt--RangeAxis__srt--MaximumMember_zeSvyCXgN658" title="Warrant price, ending"&gt;0.53&lt;/span&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--WeightedAverageExercisePriceWarrant_iE_pid_uUSDPShares_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zOkUSA1YxGAg" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Weighted average exercise price, ending"&gt;0.26&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90E_ecustom--ClassOfWarrantOrRightsContractualLifeEnding_dtY_c20220101__20220331__us-gaap--ClassOfWarrantOrRightAxis__us-gaap--WarrantMember_zy1CizYqvKpi" title="Warrant term, ending"&gt;4.1&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;


</us-gaap:ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">18050458</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crvw:WeightedAverageExercisePriceWarrant
      contextRef="AsOf2021-12-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.74</crvw:WeightedAverageExercisePriceWarrant>
    <crvw:ClassOfWarrantOrRightsContractualLifeBeginning contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember">P4Y2M12D</crvw:ClassOfWarrantOrRightsContractualLifeBeginning>
    <crvw:ClassOfWarrantOrRightsWarrantsGranted
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">3000000</crvw:ClassOfWarrantOrRightsWarrantsGranted>
    <crvw:RangeOfWarrantPricePerShareWarrantGranted
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.08</crvw:RangeOfWarrantPricePerShareWarrantGranted>
    <crvw:WarrantsGranted
      contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.08</crvw:WarrantsGranted>
    <crvw:ClassOfWarrantOrRightsContractualLifeGranted contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember">P9Y10M24D</crvw:ClassOfWarrantOrRightsContractualLifeGranted>
    <us-gaap:ClassOfWarrantOrRightOutstanding
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="Shares">21050458</us-gaap:ClassOfWarrantOrRightOutstanding>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember_srt_MinimumMember"
      decimals="INF"
      unitRef="USDPShares">0.01</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember_srt_MaximumMember"
      decimals="INF"
      unitRef="USDPShares">0.53</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <crvw:WeightedAverageExercisePriceWarrant
      contextRef="AsOf2022-03-31_us-gaap_WarrantMember"
      decimals="INF"
      unitRef="USDPShares">0.26</crvw:WeightedAverageExercisePriceWarrant>
    <crvw:ClassOfWarrantOrRightsContractualLifeEnding contextRef="From2022-01-012022-03-31_us-gaap_WarrantMember">P4Y1M6D</crvw:ClassOfWarrantOrRightsContractualLifeEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">141500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <crvw:StockGrantedDuringPeriodValueSharebasedCompensationGrossStockGrantedDuringPeriodValueSharebasedCompensationGross
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">15280</crvw:StockGrantedDuringPeriodValueSharebasedCompensationGrossStockGrantedDuringPeriodValueSharebasedCompensationGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_custom_ExercisePriceOneMember"
      decimals="INF"
      unitRef="Shares">85000</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.1</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-012022-03-31_custom_ExercisePriceTwoMember"
      decimals="INF"
      unitRef="Shares">56500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.12</us-gaap:ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit>
    <us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock_zKQQPcjtXjq1" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B6_zWmTWeHNTJwd"&gt;A summary of our stock option activity and related
information follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; border-collapse: collapse; width: 90%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Number
    of Shares Under Options&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    Average Exercise Price&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Weighted
    &lt;br/&gt;Average &lt;br/&gt;Remaining &lt;br/&gt;Contractual &lt;br/&gt;Life&lt;/b&gt;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: center"&gt;&lt;b&gt;Aggregate
    Intrinsic Value&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 40%; font-family: Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;Balance at December 31, 2021&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iS_pid_uShares_c20220101__20220331_zO1dyYUcl7Hh" style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Beginning"&gt;40,625,477&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iS_pid_uUSDPShares_c20220101__20220331_zlu9I7jBV2s7" style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Weighted Average Exercise Price, Beginning"&gt;0.12&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining_dtY_c20220101__20220331_zIH9vGlDM6mb" title="Stock Options Outstanding, Weighted Average Remaining Contractual Life, Beginning"&gt;6.7&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 3%; font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iS_c20220101__20220331_zu8rvnT4xjVj" style="width: 10%; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Aggregate Intrinsic Value, Beginning"&gt;1,283,975&lt;/td&gt;&lt;td style="width: 1%; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Granted&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross_pid_uShares_c20220101__20220331_zw08Q48BxNb2" style="font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Granted"&gt;141,500&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Forfeited/Expired&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif"&gt;&#160;&lt;/td&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Exercised&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&#x2014;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;Balance at March 31, 2022&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber_iE_uShares_c20220101__20220331_zx1pxUyT7JW4" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Ending"&gt;40,766,977&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331_z8tTfQbe9551" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Weighted Average Exercise Price, Ending"&gt;0.12&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90A_ecustom--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding_dtY_c20220101__20220331_zSo3rf8Y7Yy6" title="Stock Options Outstanding, Weighted Average Remaining Contractual Life, Ending"&gt;6.5&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue_iE_c20220101__20220331_z9Tq4GWCKkNi" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Outstanding, Aggregate Intrinsic Value, Ending"&gt;807,202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="font-family: Times New Roman, Times, Serif; text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;Vested and Exercisable at March 31, 2022&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber_iE_pid_uShares_c20220101__20220331_z57C61VS4Di" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Vested and Exercisable"&gt;26,262,810&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice_iE_pid_uUSDPShares_c20220101__20220331_zWNOeFYFXP56" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Vested and Exercisable, Weighted Average Exercise Price"&gt;0.16&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right"&gt;&lt;span id="xdx_90C_eus-gaap--SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1_dtY_c20220101__20220331_zofcDDTBnj7c" title="Stock Options Vested and Exercisable, Weighted Average Remaining Contractual Life"&gt;5.4&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="font-family: Times New Roman, Times, Serif; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue_iE_c20220101__20220331_zRofFK96wKX3" style="border-bottom: Black 2.5pt double; font-family: Times New Roman, Times, Serif; text-align: right" title="Stock Options Vested and Exercisable, Aggregate Intrinsic Value"&gt;805,202&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; font-family: Times New Roman, Times, Serif; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfShareBasedCompensationStockOptionsActivityTableTextBlock>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2021-12-31" decimals="INF" unitRef="Shares">40625477</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2021-12-31"
      decimals="INF"
      unitRef="USDPShares">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining contextRef="From2022-01-01to2022-03-31">P6Y8M12D</crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermBegining>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1283975</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross
      contextRef="From2022-01-01to2022-03-31"
      decimals="INF"
      unitRef="Shares">141500</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">40766977</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.12</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice>
    <crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding contextRef="From2022-01-01to2022-03-31">P6Y6M</crvw:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTermEnding>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">807202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber contextRef="AsOf2022-03-31" decimals="INF" unitRef="Shares">26262810</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice
      contextRef="AsOf2022-03-31"
      decimals="INF"
      unitRef="USDPShares">0.16</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice>
    <us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1 contextRef="From2022-01-01to2022-03-31">P5Y4M24D</us-gaap:SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1>
    <us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">805202</us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">55847</us-gaap:StockOptionPlanExpense>
    <us-gaap:StockOptionPlanExpense
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">52878</us-gaap:StockOptionPlanExpense>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">330670</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions>
    <us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1 contextRef="From2022-01-01to2022-03-31">P1Y6M</us-gaap:EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1>
    <us-gaap:OtherCurrentAssetsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80A_eus-gaap--OtherCurrentAssetsTextBlock_zhmvzDBgtDuf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 4 &#x2013; &lt;span id="xdx_82F_zm5CaHyB1f1b"&gt;OTHER CURRENT ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z32YCCLVt4lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12px; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_ztgdOYuqPEe8"&gt;Other current assets consist of
the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20220331_zV6m4bGdMJ3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, &lt;br/&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20211231_zwhqxxHXjiUe" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_iI_maOACzXKY_maOACzxxY_maOACz1tn_zyELIsnPEZ42" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1pt; padding-left: 5.75pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;122,382&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;235,521&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherAssetsCurrent_iTI_mtOACzXKY_mtOACzxxY_mtOACz1tn_zvLaTWROeJni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.75pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;122,383&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;235,521&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A8_zWzHDP5ixVv9" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherCurrentAssetsTextBlock>
    <us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_894_eus-gaap--ScheduleOfOtherCurrentAssetsTableTextBlock_z32YCCLVt4lh" style="font: 10pt Times New Roman, Times, Serif; margin: 0 0 12px; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BC_ztgdOYuqPEe8"&gt;Other current assets consist of
the following:&lt;/span&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20220331_zV6m4bGdMJ3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, &lt;br/&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49A_20211231_zwhqxxHXjiUe" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_405_eus-gaap--PrepaidExpenseCurrent_iI_maOACzXKY_maOACzxxY_maOACz1tn_zyELIsnPEZ42" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1pt; padding-left: 5.75pt"&gt;Prepaid expenses&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;122,382&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;235,521&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--OtherAssetsCurrent_iTI_mtOACzXKY_mtOACzxxY_mtOACz1tn_zvLaTWROeJni" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.75pt"&gt;TOTAL OTHER CURRENT ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;122,383&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;235,521&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherCurrentAssetsTableTextBlock>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">122382</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:PrepaidExpenseCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">235521</us-gaap:PrepaidExpenseCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">122383</us-gaap:OtherAssetsCurrent>
    <us-gaap:OtherAssetsCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">235521</us-gaap:OtherAssetsCurrent>
    <us-gaap:InventoryDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80F_eus-gaap--InventoryDisclosureTextBlock_zJMJldDwxW54" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 5 &#x2013; &lt;span id="xdx_828_zeFKmRGYHCte"&gt;INVENTORY&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Inventory is valued at the lower of cost, determined
on a first-in, first-out (FIFO), or net realizable value. Inventory items are analyzed to determine cost and net realizable value and
appropriate valuation adjustments are then established.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zwJrbnrfUUcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zqyWuwYZpVd6"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20220331_zH2N2YCkyTB6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, &lt;br/&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20211231_zXvkX5dGwcFf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maINzxxr_maINzDRu_z67XpoVi4Shh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1pt; padding-left: 5.75pt"&gt;Inventory Asset&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;269,917&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;349,216&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InventoryNet_iTI_mtINzxxr_mtINzDRu_zNcf87As12t2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.75pt"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;269,917&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;349,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zdXtkfvaXz55" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

</us-gaap:InventoryDisclosureTextBlock>
    <us-gaap:ScheduleOfInventoryCurrentTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_896_eus-gaap--ScheduleOfInventoryCurrentTableTextBlock_zwJrbnrfUUcl" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8BF_zqyWuwYZpVd6"&gt;Inventory consists of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 80%; margin-left: 0.5in"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="font-family: Arial, Helvetica, Sans-Serif; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49B_20220331_zH2N2YCkyTB6" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, &lt;br/&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_495_20211231_zXvkX5dGwcFf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, &lt;br/&gt;2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--InventoryFinishedGoodsNetOfReserves_iI_maINzxxr_maINzDRu_z67XpoVi4Shh" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-bottom: 1pt; padding-left: 5.75pt"&gt;Inventory Asset&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;269,917&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;349,216&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--InventoryNet_iTI_mtINzxxr_mtINzDRu_zNcf87As12t2" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.75pt"&gt;TOTAL INVENTORY&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;269,917&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;349,216&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfInventoryCurrentTableTextBlock>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">269917</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryFinishedGoodsNetOfReserves contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">349216</us-gaap:InventoryFinishedGoodsNetOfReserves>
    <us-gaap:InventoryNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">269917</us-gaap:InventoryNet>
    <us-gaap:InventoryNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">349216</us-gaap:InventoryNet>
    <us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80F_eus-gaap--PropertyPlantAndEquipmentDisclosureTextBlock_zvzGmk1gsm02" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 6 &#x2013; &lt;span id="xdx_820_zrTRSyjU6n46"&gt;PROPERTY AND EQUIPMENT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvwK72aI0AQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zM8O4Prkoude"&gt;Property and equipment consist
of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, &lt;br/&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt"&gt;Network equipment&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zeHPrayIqE75" style="width: 12%; text-align: right" title="Total property and equipment"&gt;12,850,623&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zKy4yloBsM3e" style="width: 12%; text-align: right"&gt;12,620,259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zCGScEZBC1Ll" style="text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z4Yqm4jyYMr8" style="text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZgX9NE8C0D4" style="text-align: right"&gt;232,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwBUzGfkspw8" style="text-align: right"&gt;232,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Test equipment &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestEquipmentMember_zTHDeo0WgEY9" style="text-align: right"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestEquipmentMember_zYYbmt1IBP6j" style="text-align: right"&gt;204,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zREOB4QBbIJb" style="text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zPjfzW4aajk8" style="text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Warehouse equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zBBtfU6uoCnk" style="text-align: right"&gt;9,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_z5WI8cB0vo1c" style="text-align: right"&gt;9,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zTQj5UeNUHJ6" style="border-bottom: Black 1pt solid; text-align: right"&gt;5,122&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW3z1WoOtvZ4" style="border-bottom: Black 1pt solid; text-align: right"&gt;5,121&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;TOTAL PROPERTY AND EQUIPMENT&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20220331_zLphUWTJX1Zk" style="text-align: right"&gt;13,419,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zt2XMDbMQeyf" style="text-align: right"&gt;13,393,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20220331_zTZrmVdfwrBi" style="border-bottom: Black 1pt solid; text-align: right" title="Less : Accumulated depreciation"&gt;(12,415,814&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20211231_ziLidw99V0r" style="border-bottom: Black 1pt solid; text-align: right" title="Less : Accumulated depreciation"&gt;(12,254,964&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;TOTAL PROPERTY AND EQUIPMENT, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20220331_zT06GLieg745" style="border-bottom: Black 2.5pt double; text-align: right" title="Total property and equipment, net"&gt;1,003,951&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20211231_zpcYnzde0Elb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,138,891&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AB_zkfpsb3UMMYg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Depreciation expense for the three months ended March
31, 2022 and 2021 was $&lt;span id="xdx_906_eus-gaap--DepreciationDepletionAndAmortization_c20220101__20220331_ziVPfRfHkVzk" title="Depreciation expense"&gt;134,941&lt;/span&gt; and $&lt;span id="xdx_901_eus-gaap--DepreciationDepletionAndAmortization_c20210101__20210331_zmMJzrvKily7"&gt;149,902&lt;/span&gt;, respectively.&lt;/p&gt;

</us-gaap:PropertyPlantAndEquipmentDisclosureTextBlock>
    <us-gaap:PropertyPlantAndEquipmentTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_897_eus-gaap--PropertyPlantAndEquipmentTextBlock_zvwK72aI0AQf" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&lt;span id="xdx_8B7_zM8O4Prkoude"&gt;Property and equipment consist
of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; border-collapse: collapse; width: 100%"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, &lt;br/&gt;2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt"&gt;Network equipment&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zeHPrayIqE75" style="width: 12%; text-align: right" title="Total property and equipment"&gt;12,850,623&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--NetworkEquipmentMember_zKy4yloBsM3e" style="width: 12%; text-align: right"&gt;12,620,259&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Office equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_zCGScEZBC1Ll" style="text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--OfficeEquipmentMember_z4Yqm4jyYMr8" style="text-align: right"&gt;229,240&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Vehicles&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zZgX9NE8C0D4" style="text-align: right"&gt;232,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--VehiclesMember_zwBUzGfkspw8" style="text-align: right"&gt;232,411&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Test equipment &lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestEquipmentMember_zTHDeo0WgEY9" style="text-align: right"&gt;&#160;&lt;span style="-sec-ix-hidden: xdx2ixbrl0632"&gt;&#x2014;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--TestEquipmentMember_zYYbmt1IBP6j" style="text-align: right"&gt;204,455&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Furniture&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zREOB4QBbIJb" style="text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_985_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--FurnitureAndFixturesMember_zPjfzW4aajk8" style="text-align: right"&gt;92,846&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Warehouse equipment&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_zBBtfU6uoCnk" style="text-align: right"&gt;9,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__custom--WarehouseEquipmentMember_z5WI8cB0vo1c" style="text-align: right"&gt;9,523&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Leasehold improvements&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20220331__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zTQj5UeNUHJ6" style="border-bottom: Black 1pt solid; text-align: right"&gt;5,122&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231__us-gaap--PropertyPlantAndEquipmentByTypeAxis__us-gaap--LeaseholdImprovementsMember_zW3z1WoOtvZ4" style="border-bottom: Black 1pt solid; text-align: right"&gt;5,121&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;TOTAL PROPERTY AND EQUIPMENT&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--PropertyPlantAndEquipmentGross_iI_maPPE_c20220331_zLphUWTJX1Zk" style="text-align: right"&gt;13,419,765&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--PropertyPlantAndEquipmentGross_iI_c20211231_zt2XMDbMQeyf" style="text-align: right"&gt;13,393,856&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Less: accumulated depreciation&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20220331_zTZrmVdfwrBi" style="border-bottom: Black 1pt solid; text-align: right" title="Less : Accumulated depreciation"&gt;(12,415,814&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_eus-gaap--AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_iNI_di_msPPE_c20211231_ziLidw99V0r" style="border-bottom: Black 1pt solid; text-align: right" title="Less : Accumulated depreciation"&gt;(12,254,964&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;TOTAL PROPERTY AND EQUIPMENT, NET&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20220331_zT06GLieg745" style="border-bottom: Black 2.5pt double; text-align: right" title="Total property and equipment, net"&gt;1,003,951&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--PropertyPlantAndEquipmentNet_iTI_mtPPE_c20211231_zpcYnzde0Elb" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,138,891&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:PropertyPlantAndEquipmentTextBlock>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_custom_NetworkEquipmentMember"
      decimals="0"
      unitRef="USD">12850623</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_NetworkEquipmentMember"
      decimals="0"
      unitRef="USD">12620259</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">229240</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_OfficeEquipmentMember"
      decimals="0"
      unitRef="USD">229240</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_VehiclesMember"
      decimals="0"
      unitRef="USD">232411</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_VehiclesMember"
      decimals="0"
      unitRef="USD">232411</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_TestEquipmentMember"
      decimals="0"
      unitRef="USD">204455</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">92846</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_FurnitureAndFixturesMember"
      decimals="0"
      unitRef="USD">92846</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_custom_WarehouseEquipmentMember"
      decimals="0"
      unitRef="USD">9523</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_custom_WarehouseEquipmentMember"
      decimals="0"
      unitRef="USD">9523</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2022-03-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">5122</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross
      contextRef="AsOf2021-12-31_us-gaap_LeaseholdImprovementsMember"
      decimals="0"
      unitRef="USD">5121</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">13419765</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:PropertyPlantAndEquipmentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">13393856</us-gaap:PropertyPlantAndEquipmentGross>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">12415814</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">12254964</us-gaap:AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1003951</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:PropertyPlantAndEquipmentNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1138891</us-gaap:PropertyPlantAndEquipmentNet>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">134941</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:DepreciationDepletionAndAmortization
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">149902</us-gaap:DepreciationDepletionAndAmortization>
    <us-gaap:OtherAssetsDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--OtherAssetsDisclosureTextBlock_ziJKaVZxPxuk" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 7 &#x2013; &lt;span id="xdx_82A_zuJaMIXGICU8"&gt;OTHER ASSETS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_893_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zl9wZk2kDUei" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zhQMMBx0Qo5l"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maIntang_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_z57wa8Nk7Ws9" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Cost"&gt;1,310,436&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIntang_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zeufsBPHXrl1" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Accumulated Amortization"&gt;358,380&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtIntang_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_z20NjPMvwmD8" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Net"&gt;952,056&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zkEky5vnz2Ph" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;1,310,436&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zt6WX8ngbmk7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;358,380&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20220331_z94srnH2zow2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;952,056&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-left: 5.4pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zBgLTUWx2eyb" style="width: 11%; text-align: right" title="Cost"&gt;1,254,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zp6L4Sio9Fn2" style="width: 11%; text-align: right" title="Accumulated Amortization"&gt;343,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_ziwJFzLAX3n1" style="width: 11%; text-align: right" title="Net"&gt;910,398&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_z8DP5SLNiRQe" style="border-bottom: Black 1pt solid; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zIrSIa6kUtck" style="border-bottom: Black 1pt solid; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zK8npUJeN8x3" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231_zEgNZ47Bu1j7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,338,072&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zQX0n1mIqjO1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;427,674&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20211231_ztF9Mb72ZQC9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;910,398&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_8AD_zH0wWBG2Uk84" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zI9bJPpldFL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zgxlKkzKfpXi"&gt;Other assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-left: 5.4pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsNoncurrentGross_iI_maOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zuOp7KWYywo5" style="width: 11%; text-align: right" title="Cost"&gt;1,352,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OtherAssetsAccumulatedAmortization_iI_msOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zTg2puS07d61" style="width: 11%; text-align: right" title="Accumulated Amortization"&gt;1,295,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_mtOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zZqe9t3OqgL5" style="width: 11%; text-align: right" title="Net"&gt;56,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Deferred sales commission&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OtherAssetsNoncurrentGross_iI_maOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zZNGzwxhOuq9" style="text-align: right"&gt;122,778&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsAccumulatedAmortization_iI_msOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zYX8k0zuod5g" style="text-align: right"&gt;18,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_mtOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zjDUvQryJXe4" style="text-align: right"&gt;103,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherAssetsNoncurrentGross_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zCbHc06s0HV3" style="text-align: right"&gt;249,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OtherAssetsAccumulatedAmortization_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_z0aJidDmpnA5" style="text-align: right"&gt;173,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zPPEQuJlQgog" style="text-align: right"&gt;76,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Security deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OtherAssetsNoncurrentGross_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zoOQFfPBARTc" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsAccumulatedAmortization_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_z69Lzyw8gbm1" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zia7eelJp0ec" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherAssetsNoncurrentGross_iI_c20220331_z7I9JHD5eTCj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,770,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsAccumulatedAmortization_iI_c20220331_zAItaMCQJkG1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,487,549&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20220331_zgBdPWlIMcWi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;283,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-left: 5.4pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zxxUEFUkntli" style="width: 11%; text-align: right"&gt;1,352,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zHWl0vAswY67" style="width: 11%; text-align: right"&gt;1,283,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_z5sJUsR0vbQf" style="width: 11%; text-align: right"&gt;68,901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Deferred sales commissions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zapVdw7Zy245" style="text-align: right"&gt;122,778&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zUYSIPxxZorb" style="text-align: right"&gt;18,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zHDFY9Y4oVse" style="text-align: right"&gt;103,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_z4eZG5tmvhF3" style="text-align: right"&gt;249,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zMte8ZqNNDCe" style="text-align: right"&gt;169,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zA5YnqIHxukh" style="text-align: right"&gt;80,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Security deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_ztknujjwyr68" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zgccQ3NxRL6i" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0708"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zQ2HwKlqJQj1" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherAssetsNoncurrentGross_iI_c20211231_zz49s3qQ23J2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,770,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231_zr14JHm0rWM7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,471,379&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231_zFa3aNr9hkc7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;299,563&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A9_zvsadg96JKx6" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:OtherAssetsDisclosureTextBlock>
    <us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_893_eus-gaap--ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock_zl9wZk2kDUei" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B7_zhQMMBx0Qo5l"&gt;Intangible assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_maIntang_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_z57wa8Nk7Ws9" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Cost"&gt;1,310,436&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_msIntang_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zeufsBPHXrl1" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Accumulated Amortization"&gt;358,380&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_mtIntang_c20220331__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_z20NjPMvwmD8" style="border-bottom: Black 1pt solid; width: 11%; text-align: right" title="Net"&gt;952,056&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98B_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20220331_zkEky5vnz2Ph" style="border-bottom: Black 2.5pt double; text-align: right" title="Cost"&gt;1,310,436&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20220331_zt6WX8ngbmk7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;358,380&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20220331_z94srnH2zow2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;952,056&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-left: 5.4pt"&gt;Patents and trademarks&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zBgLTUWx2eyb" style="width: 11%; text-align: right" title="Cost"&gt;1,254,327&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_zp6L4Sio9Fn2" style="width: 11%; text-align: right" title="Accumulated Amortization"&gt;343,929&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__custom--PatentsTrademarksMember_ziwJFzLAX3n1" style="width: 11%; text-align: right" title="Net"&gt;910,398&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other intangible assets&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_z8DP5SLNiRQe" style="border-bottom: Black 1pt solid; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zIrSIa6kUtck" style="border-bottom: Black 1pt solid; text-align: right"&gt;83,745&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20211231__us-gaap--FiniteLivedIntangibleAssetsByMajorClassAxis__us-gaap--OtherIntangibleAssetsMember_zK8npUJeN8x3" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0674"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL INTANGIBLE ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--FiniteLivedIntangibleAssetsGross_iI_c20211231_zEgNZ47Bu1j7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,338,072&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--FiniteLivedIntangibleAssetsAccumulatedAmortization_iI_c20211231_zQX0n1mIqjO1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;427,674&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98C_eus-gaap--FiniteLivedIntangibleAssetsNet_iTI_c20211231_ztF9Mb72ZQC9" style="border-bottom: Black 2.5pt double; text-align: right"&gt;910,398&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:ScheduleOfFiniteLivedIntangibleAssetsTableTextBlock>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2022-03-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">1310436</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">358380</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2022-03-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">952056</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1310436</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">358380</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">952056</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">1254327</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">343929</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet
      contextRef="AsOf2021-12-31_custom_PatentsTrademarksMember"
      decimals="0"
      unitRef="USD">910398</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:FiniteLivedIntangibleAssetsGross
      contextRef="AsOf2021-12-31_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">83745</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_us-gaap_OtherIntangibleAssetsMember"
      decimals="0"
      unitRef="USD">83745</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1338072</us-gaap:FiniteLivedIntangibleAssetsGross>
    <us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">427674</us-gaap:FiniteLivedIntangibleAssetsAccumulatedAmortization>
    <us-gaap:FiniteLivedIntangibleAssetsNet contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">910398</us-gaap:FiniteLivedIntangibleAssetsNet>
    <us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_895_eus-gaap--ScheduleOfOtherAssetsNoncurrentTextBlock_zI9bJPpldFL4" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B8_zgxlKkzKfpXi"&gt;Other assets consist of the following:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-left: 5.4pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsNoncurrentGross_iI_maOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zuOp7KWYywo5" style="width: 11%; text-align: right" title="Cost"&gt;1,352,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98E_ecustom--OtherAssetsAccumulatedAmortization_iI_msOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zTg2puS07d61" style="width: 11%; text-align: right" title="Accumulated Amortization"&gt;1,295,212&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_mtOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zZqe9t3OqgL5" style="width: 11%; text-align: right" title="Net"&gt;56,829&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Deferred sales commission&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OtherAssetsNoncurrentGross_iI_maOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zZNGzwxhOuq9" style="text-align: right"&gt;122,778&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_ecustom--OtherAssetsAccumulatedAmortization_iI_msOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zYX8k0zuod5g" style="text-align: right"&gt;18,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_mtOther_c20220331__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zjDUvQryJXe4" style="text-align: right"&gt;103,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherAssetsNoncurrentGross_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zCbHc06s0HV3" style="text-align: right"&gt;249,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OtherAssetsAccumulatedAmortization_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_z0aJidDmpnA5" style="text-align: right"&gt;173,496&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zPPEQuJlQgog" style="text-align: right"&gt;76,503&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Security deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_ecustom--OtherAssetsNoncurrentGross_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zoOQFfPBARTc" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsAccumulatedAmortization_iI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_z69Lzyw8gbm1" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0693"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_988_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20220331__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zia7eelJp0ec" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_980_ecustom--OtherAssetsNoncurrentGross_iI_c20220331_z7I9JHD5eTCj" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,770,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_988_ecustom--OtherAssetsAccumulatedAmortization_iI_c20220331_zAItaMCQJkG1" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,487,549&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20220331_zgBdPWlIMcWi" style="border-bottom: Black 2.5pt double; text-align: right"&gt;283,393&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 90%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="11" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Cost&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Accumulated Amortization&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Net&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 46%; text-align: justify; padding-left: 5.4pt"&gt;Deferred installation costs&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_983_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zxxUEFUkntli" style="width: 11%; text-align: right"&gt;1,352,041&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_zHWl0vAswY67" style="width: 11%; text-align: right"&gt;1,283,140&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 5%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredInstallationCostsMember_z5sJUsR0vbQf" style="width: 11%; text-align: right"&gt;68,901&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Deferred sales commissions&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98D_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zapVdw7Zy245" style="text-align: right"&gt;122,778&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zUYSIPxxZorb" style="text-align: right"&gt;18,841&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--DeferredSalesCommissionsMember_zHDFY9Y4oVse" style="text-align: right"&gt;103,937&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Prepaid license fee&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_z4eZG5tmvhF3" style="text-align: right"&gt;249,999&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zMte8ZqNNDCe" style="text-align: right"&gt;169,398&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--PrepaidLicenseFeeMember_zA5YnqIHxukh" style="text-align: right"&gt;80,601&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Security deposit&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_989_ecustom--OtherAssetsNoncurrentGross_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_ztknujjwyr68" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98C_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zgccQ3NxRL6i" style="border-bottom: Black 1pt solid; text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0708"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231__us-gaap--BalanceSheetLocationAxis__custom--SecurityDepositMember_zQ2HwKlqJQj1" style="border-bottom: Black 1pt solid; text-align: right"&gt;46,124&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;TOTAL OTHER ASSETS&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_ecustom--OtherAssetsNoncurrentGross_iI_c20211231_zz49s3qQ23J2" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,770,942&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_982_ecustom--OtherAssetsAccumulatedAmortization_iI_c20211231_zr14JHm0rWM7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;1,471,379&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--OtherAssetsMiscellaneousNoncurrent_iTI_c20211231_zFa3aNr9hkc7" style="border-bottom: Black 2.5pt double; text-align: right"&gt;299,563&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:ScheduleOfOtherAssetsNoncurrentTextBlock>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2022-03-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1352041</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1295212</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2022-03-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">56829</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2022-03-31_custom_DeferredSalesCommissionsMember"
      decimals="0"
      unitRef="USD">122778</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_DeferredSalesCommissionsMember"
      decimals="0"
      unitRef="USD">18841</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2022-03-31_custom_DeferredSalesCommissionsMember"
      decimals="0"
      unitRef="USD">103937</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2022-03-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">249999</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2022-03-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">173496</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2022-03-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">76503</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2022-03-31_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</crvw:OtherAssetsNoncurrentGross>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2022-03-31_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1770942</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1487549</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">283393</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2021-12-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1352041</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">1283140</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2021-12-31_custom_DeferredInstallationCostsMember"
      decimals="0"
      unitRef="USD">68901</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2021-12-31_custom_DeferredSalesCommissionsMember"
      decimals="0"
      unitRef="USD">122778</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_DeferredSalesCommissionsMember"
      decimals="0"
      unitRef="USD">18841</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2021-12-31_custom_DeferredSalesCommissionsMember"
      decimals="0"
      unitRef="USD">103937</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2021-12-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">249999</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization
      contextRef="AsOf2021-12-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">169398</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2021-12-31_custom_PrepaidLicenseFeeMember"
      decimals="0"
      unitRef="USD">80601</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross
      contextRef="AsOf2021-12-31_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</crvw:OtherAssetsNoncurrentGross>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent
      contextRef="AsOf2021-12-31_custom_SecurityDepositMember"
      decimals="0"
      unitRef="USD">46124</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <crvw:OtherAssetsNoncurrentGross contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1770942</crvw:OtherAssetsNoncurrentGross>
    <crvw:OtherAssetsAccumulatedAmortization contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">1471379</crvw:OtherAssetsAccumulatedAmortization>
    <us-gaap:OtherAssetsMiscellaneousNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">299563</us-gaap:OtherAssetsMiscellaneousNoncurrent>
    <us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_801_eus-gaap--AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock_zRm2tDxzSsMe" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 8 &#x2013; &lt;span id="xdx_820_zl2e6vxJRnY6"&gt;OTHER CURRENT LIABILITIES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgIHfpXTXtmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current liabilities consist of the following:	&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20220331_ztzDkbZ83Jbe" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20211231_zexp3VJ1qayd" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zFVqrZItfiua" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,608,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,947,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedInterestRelatedParties_iI_maOLCzZoC_zqUfSK6pGv25" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued interest, related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;255,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,528&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AllowanceSystemRemovalCurrent_iI_maOLCzZoC_zWBg990Lwltf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Allowance for system removal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedVacationCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zHaQfQr0q3Oc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued paid time off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184,758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredCompensationLiabilityCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zekroHo9KeA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred officer compensation &lt;sup id="xdx_F4F_zqqiuUlkg1Ja"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zmxzxIJMiiE5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,394,694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;983,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maOLCzZoC_zDxLRe9Go8r3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued taxes (other than income taxes)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zB5Wy31o2Jn5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance premium financing &lt;sup id="xdx_F4F_zfOxHgSRGNh9"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zHlbrInKnvc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;62,875&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;70,388&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzZoC_z0dO2ocYBKFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,755,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,740,218&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-top: 3pt; margin-bottom: 6pt; width: 1in"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 22pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&lt;sup id="xdx_F0C_zBqSGUPQKxse"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zDSEpLkq3R9a" style="font-size: 9pt"&gt;Salary for Steve Johnson, CEO, between
February 15, 2018 and September 30, 2020.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 22pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&lt;sup id="xdx_F01_zcVj3KMeMstj"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zmikFtxENdfd" style="font-size: 9pt"&gt;Renewal of directors and officer&#x2019;s
insurance.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;p id="xdx_8AC_zsYuCZFPw5Jb" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:AccountsPayableAccruedLiabilitiesAndOtherLiabilitiesDisclosureCurrentTextBlock>
    <us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89D_eus-gaap--ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock_zgIHfpXTXtmk" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Other current liabilities consist of the following:	&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"/&gt;



&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_492_20220331_ztzDkbZ83Jbe" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_49D_20211231_zexp3VJ1qayd" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_402_eus-gaap--InterestPayableCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zFVqrZItfiua" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 56%; text-align: justify; padding-left: 5.4pt"&gt;Accrued interest&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;10,608,610&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="width: 12%; text-align: right"&gt;9,947,730&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_ecustom--AccruedInterestRelatedParties_iI_maOLCzZoC_zqUfSK6pGv25" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued interest, related parties&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;255,653&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;228,528&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_ecustom--AllowanceSystemRemovalCurrent_iI_maOLCzZoC_zWBg990Lwltf" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Allowance for system removal&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;54,802&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_406_eus-gaap--AccruedVacationCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zHaQfQr0q3Oc" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued paid time off&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;184,758&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;173,904&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--DeferredCompensationLiabilityCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zekroHo9KeA2" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Deferred officer compensation &lt;sup id="xdx_F4F_zqqiuUlkg1Ja"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;139,041&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--ContractWithCustomerLiabilityCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zmxzxIJMiiE5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Deferred revenue&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;1,394,694&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;983,667&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40D_eus-gaap--AccrualForTaxesOtherThanIncomeTaxesCurrent_iI_maOLCzZoC_zDxLRe9Go8r3" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;Accrued taxes (other than income taxes)&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;55,320&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;38,367&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_401_eus-gaap--AccruedInsuranceCurrentAndNoncurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zB5Wy31o2Jn5" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: justify; padding-left: 5.4pt"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;Insurance premium financing &lt;sup id="xdx_F4F_zfOxHgSRGNh9"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0739"&gt;&#x2014;&lt;/span&gt;&#160;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;103,791&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OtherAccruedLiabilitiesCurrent_iI_maOLCzoVW_maOLCzQNX_maOLCzbnp_maOLCzZoC_zHlbrInKnvc9" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Other accrued liabilities&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;62,875&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; text-align: right"&gt;70,388&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_403_eus-gaap--OtherLiabilitiesCurrent_iTI_mtOLCzZoC_z0dO2ocYBKFe" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;TOTAL OTHER CURRENT LIABILITIES&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;12,755,753&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;11,740,218&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;div style="margin-top: 3pt; margin-bottom: 6pt; width: 1in"&gt;&lt;div style="border-top: Black 1pt solid; font-size: 1pt"&gt;&#160;&lt;/div&gt;&lt;/div&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"/&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 0; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 22pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&lt;sup id="xdx_F0C_zBqSGUPQKxse"&gt;(1)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F12_zDSEpLkq3R9a" style="font-size: 9pt"&gt;Salary for Steve Johnson, CEO, between
February 15, 2018 and September 30, 2020.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0; margin-bottom: 12pt; width: 100%"&gt;&lt;tr style="vertical-align: top; text-align: justify"&gt;
&lt;td style="width: 0"/&gt;&lt;td style="width: 22pt; text-align: left"&gt;&lt;span style="font-size: 9pt"&gt;&lt;sup id="xdx_F01_zcVj3KMeMstj"&gt;(2)&lt;/sup&gt;&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: justify"&gt;&lt;span id="xdx_F19_zmikFtxENdfd" style="font-size: 9pt"&gt;Renewal of directors and officer&#x2019;s
insurance.&lt;/span&gt;&lt;/td&gt;
&lt;/tr&gt;&lt;/table&gt;

</us-gaap:ScheduleOfAccountsPayableAndAccruedLiabilitiesTableTextBlock>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">10608610</us-gaap:InterestPayableCurrent>
    <us-gaap:InterestPayableCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">9947730</us-gaap:InterestPayableCurrent>
    <crvw:AccruedInterestRelatedParties contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">255653</crvw:AccruedInterestRelatedParties>
    <crvw:AccruedInterestRelatedParties contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">228528</crvw:AccruedInterestRelatedParties>
    <crvw:AllowanceSystemRemovalCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">54802</crvw:AllowanceSystemRemovalCurrent>
    <crvw:AllowanceSystemRemovalCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">54802</crvw:AllowanceSystemRemovalCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">184758</us-gaap:AccruedVacationCurrent>
    <us-gaap:AccruedVacationCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">173904</us-gaap:AccruedVacationCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2022-03-31"
      decimals="0"
      id="Fact000730"
      unitRef="USD">139041</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:DeferredCompensationLiabilityCurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000731"
      unitRef="USD">139041</us-gaap:DeferredCompensationLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">1394694</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:ContractWithCustomerLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">983667</us-gaap:ContractWithCustomerLiabilityCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">55320</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">38367</us-gaap:AccrualForTaxesOtherThanIncomeTaxesCurrent>
    <us-gaap:AccruedInsuranceCurrentAndNoncurrent
      contextRef="AsOf2021-12-31"
      decimals="0"
      id="Fact000740"
      unitRef="USD">103791</us-gaap:AccruedInsuranceCurrentAndNoncurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">62875</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherAccruedLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">70388</us-gaap:OtherAccruedLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">12755753</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:OtherLiabilitiesCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">11740218</us-gaap:OtherLiabilitiesCurrent>
    <us-gaap:IncomeTaxDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_800_eus-gaap--IncomeTaxDisclosureTextBlock_zedg0NdxyUP7" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 9 &#x2013; &lt;span id="xdx_823_zarbpZNR665a"&gt;INCOME TAXES&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Deferred income tax assets and liabilities are determined
based upon differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax
rates and laws that will be in effect when the differences are expected to reverse. We do not expect to pay any significant federal or
state income tax for 2022 because of the losses recorded during the three months ended March 31, 2022 and net operating loss carry forwards
from prior years. Accounting standards require the consideration of a valuation allowance for deferred tax assets if it is "more
likely than not" that some component or all the benefits of deferred tax assets will not be realized. As of March 31, 2022, we maintained
a full valuation allowance for all deferred tax assets. Based on these requirements, no provision or benefit for income taxes has been
recorded. There were no recorded unrecognized tax benefits at the end of the reporting period.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Tax Cuts and Jobs Act (the
&#x201c;Act&#x201d;) was signed into law on December 22, 2017. Among its numerous changes to the Internal Revenue Code, the Act
reduces U.S. corporate rates from &lt;span id="xdx_90B_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20170101__20171231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zHi7Xqnqxszl" title="Percentage of corporate tax rate"&gt;35&lt;/span&gt;%
to &lt;span id="xdx_90E_eus-gaap--EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate_pid_dp_uPure_c20180101__20181231__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_z5sxG3OspKd9"&gt;21&lt;/span&gt;%.
Additionally, the Act limits the use of net operating loss carry backs, however any future net operating losses will instead be
carried forward indefinitely. Net operating losses generated from January 1, 2018 are limited to offset &lt;span id="xdx_90F_ecustom--PercentageOfOperatingLossCarryforwardsLimitation_iI_pid_dp_uPure_c20180102__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_z95bLYBKgUL" title="Percentage of operating loss carryforwards limitation"&gt;80&lt;/span&gt;%
of current income, with the remainder of the net operating loss continuing to carry forward indefinitely. Net operating losses
incurred before January 1, 2018 are not subject to the &lt;span id="xdx_907_ecustom--PercentageOfOperatingLossCarryforwardsLimitation_iI_pid_dp_uPure_c20180102__us-gaap--IncomeTaxAuthorityAxis__us-gaap--InternalRevenueServiceIRSMember_zopdZOAE62Z5"&gt;80&lt;/span&gt;%
limitations and will begin to expire in 2029. Based on an initial assessment of the Act, the Company believes that the most
significant impact on the Company&#x2019;s unaudited condensed consolidated financial statements will be limitations in tax deductions
on interest expense. Under the Act, interest deductions disallowed from current income will carryforward indefinitely. The Act did
not impact management&#x2019;s valuation allowance position.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The effective tax rate for the three months ended
March 31, 2022 was different from the federal statutory rate due primarily to change in the valuation allowance and nondeductible interest
and amortization expense.&lt;/p&gt;

</us-gaap:IncomeTaxDisclosureTextBlock>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2017-01-012017-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="INF"
      unitRef="Pure">0.35</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
      contextRef="From2018-01-012018-12-31_us-gaap_InternalRevenueServiceIRSMember"
      decimals="INF"
      unitRef="Pure">0.21</us-gaap:EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate>
    <crvw:PercentageOfOperatingLossCarryforwardsLimitation
      contextRef="AsOf2018-01-02_us-gaap_InternalRevenueServiceIRSMember"
      decimals="INF"
      unitRef="Pure">0.80</crvw:PercentageOfOperatingLossCarryforwardsLimitation>
    <crvw:PercentageOfOperatingLossCarryforwardsLimitation
      contextRef="AsOf2018-01-02_us-gaap_InternalRevenueServiceIRSMember"
      decimals="INF"
      unitRef="Pure">0.80</crvw:PercentageOfOperatingLossCarryforwardsLimitation>
    <crvw:AgreementWithPdlBiopharmaTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80F_ecustom--AgreementWithPdlBiopharmaTextBlock_zc7D731FUFbg" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 10 &#x2013; &lt;span id="xdx_823_zbmi7Vj2PaLe"&gt;AGREEMENT WITH PDL BIOPHARMA,
INC.&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;On June 26, 2015, we entered into a Credit Agreement (as subsequently
amended) with PDL BioPharma, Inc. ("PDL"), as administrative agent and lender ("the Lender") (the "PDL Credit
Agreement"). Under the PDL Credit Agreement the Lender made available to us up to $&lt;span id="xdx_904_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_pn6n6_c20150626__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember_zmqrfB9ofnd3" title="Amount available under credit agreement"&gt;40&lt;/span&gt; million in two tranches of $&lt;span id="xdx_908_eus-gaap--DebtInstrumentUnusedBorrowingCapacityAmount_iI_pn6n6_c20150626__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_z09jI28LVeCi" title="Amount available under credit agreement"&gt;20&lt;/span&gt; million each.
Tranche One was funded on October 8, 2015 (the "Tranche One Loan"). Pursuant to the terms of the PDL Credit Agreement and having
not met the Tranche Two Milestones by July 26, 2017, the Tranche Two funding was terminated in full.&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;From October 8, 2015 through May 14, 2019, the outstanding borrowings
under the Tranche One Loan bore interest at the rate of &lt;span id="xdx_90F_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20151008__20190513__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zBBmue0Q90Wc" title="Interest rate during period"&gt;13.5&lt;/span&gt;% per annum, payable quarterly. On May 15, 2019, pursuant to the terms of
the Fifth Amendment to the PDL Credit Agreement (see below for additional details), the interest increased to &lt;span id="xdx_909_eus-gaap--DebtInstrumentInterestRateStatedPercentage_iI_dp_c20190515__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_z3bgvTwS00A9" title="Debt instrument interest rate"&gt;15.5&lt;/span&gt;% per annum, payable
quarterly. Also, on May 15, 2019, pursuant to the terms of the Fourteenth Amendment to the PDL Modification Agreement (see below for additional
details), the minimum cash balance requirement of $&lt;span id="xdx_90D_ecustom--MinimumCashBalanceRequiredBeforeModification_iI_pp0p0_c20190515__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zzUfmEfoq2I6" title="Minimum cash balance required before modification"&gt;750,000&lt;/span&gt; was reduced to $&lt;span id="xdx_907_eus-gaap--CompensatingBalanceAmount_iI_pp0p0_c20190515__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--LongtermDebtTypeAxis__custom--TrancheOneMember_zXDIHtpQNAw7" title="Minimum cash balance required"&gt;0&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;On January 31, 2021, the Company, the Borrower, the Subsidiary
Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Third Amendment to Modification Agreement (the &#x201c;Twenty-Third
Modification Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the
dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July 31, 2018
and January 31, 2021 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s
(i) interest payments that would otherwise be due under the Credit Agreement on December 31, 2018, March 31, 2019, June 30, 2019, September
30, 2019, December 31, 2019, March 31, 2020, June 30, 2020, September 30, 2020, and October 7, 2020 and (ii) payments for principal and
for any other Obligations then outstanding under the Tranche One Loan and the Tranche Three Loans that would otherwise be due under the
Credit Agreement on October 7, 2020, would each be deferred until May 31, 2021 (the end of the extended Modification Period) and that
such deferrals would be a Covered Event. The Company has evaluated the Twenty-Third Modification Agreement Amendment and as the effective
borrowing rate under the restructured agreement is less than the effective borrowing rate on the old agreement, a concession is deemed
to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement is to be accounted for as a troubled debt
restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;On May 25, 2021, the Company, the Borrower, the Subsidiary Guarantor,
the Lender and the Tranche Three Lenders entered into a Twenty-Fourth Amendment to Modification Agreement (the &#x201c;Twenty-Fourth Modification
Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the dates on which
the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July 31, 2018 and November
30, 2021 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s (i) interest
payments that would otherwise be due under the Credit Agreement on December 31, 2018, March 31, 2019, June 30, 2019, September 30, 2019,
December 31, 2019, March 31, 2020, June 30, 2020, September 30, 2020, October 7, 2020, and (ii) payments for principal and for any other
Obligations then outstanding under the Tranche One Loan and the Tranche Three Loans that would otherwise be due under the Credit Agreement
on October 7, 2020, would each be deferred until November 30, 2021 (the end of the extended Modification) and that such deferrals would
be a Covered Event. The Company has evaluated the Twenty-Fourth Modification Agreement Amendment and as the effective borrowing rate under
the restructured agreement is less than the effective borrowing rate on the old agreement, a concession is deemed to have been granted
under ASC 470-60-55-10. As a concession has been granted, the agreement is to be accounted for as a troubled debt restructuring by debtors
(TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;On November&#160;29, 2021, the Company, the Borrower, the Subsidiary
Guarantor, the Lender and the Tranche Three Lenders entered into a Twenty-Fifth Amendment to Modification Agreement (the &#x201c;Twenty-Fifth
Modification Agreement Amendment&#x201d;), pursuant to which the parties agreed to amend the Modification Agreement to provide that the
dates on which the Lender may elect, in the Lender&#x2019;s sole discretion, to terminate the Modification Period would be July&#160;31,
2018 and June&#160;30, 2022 (with each such date permitted to be extended by the Lender in its sole discretion); and that the Borrower&#x2019;s
(i)&#160;interest payments that would otherwise be due under the Credit Agreement on December&#160;31, 2018, March&#160;31, 2019, June&#160;30,
2019, September&#160;30, 2019, December&#160;31, 2019, March&#160;31, 2020, June&#160;30, 2020, September&#160;30, 2020 and October&#160;7,
2020 and (ii)&#160;payments for principal and for any other Obligations then outstanding under the Tranche One Loan and the Tranche Three
Loans that would otherwise be due under the Credit Agreement on October&#160;7, 2020, would each be deferred until June&#160;30, 2022
(the end of the extended Modification) and that such deferrals would be a covered event. The Company has evaluated the Twenty-Fifth Modification
Agreement Amendment and as the effective borrowing rate under the restructured agreement is less than the effective borrowing rate on
the old agreement, a concession is deemed to have been granted under ASC 470-60-55-10. As a concession has been granted, the agreement
is to be accounted for as a troubled debt restructuring by debtors (TDR) under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Accounting Treatment &lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;In connection with the PDL Credit Agreement, as amended,
we issued the PDL Warrant to the Lender. The fair value of the PDL Warrant at issuance was $&lt;span id="xdx_906_ecustom--DeferredIssuanceCosts_iI_pp0p0_c20220331__us-gaap--CreditFacilityAxis__custom--PDLBioPharmaIncMember__us-gaap--ClassOfWarrantOrRightAxis__custom--WarrantPurchaseAgreementMember_z3bHHD4m9ME8" title="Deferred issuance costs"&gt;1,600,000&lt;/span&gt;
which has been recorded as deferred issuance costs in the accompanying unaudited condensed consolidated financial statements. As of
March 31, 2022, the Amended PDL Warrant has not been exercised.&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;As of March 31, 2022, the Company and Lender had entered
into twenty-fifth amendments to the PDL Modification Agreement (as detailed above), resulting in restructuring of the PDL Credit
Agreement and the accounting treatment of the related costs. Under debt modification/troubled debt guidance, we determined that the
first of the eight amendments had no cash flow impact, and therefore, had no impact on accounting. Amendments nine through ten
qualified for modification accounting, while the final thirteen amendments qualified for troubled debt restructuring accounting. As
appropriate, we expensed the legal costs paid to third parties. For the three months ended March 31, 2022 and 2021, pursuant to the
terms of the PDL Modification Agreement, as amended, $&lt;span id="xdx_901_eus-gaap--InterestExpense_pp0p0_c20220101__20220331__us-gaap--TypeOfArrangementAxis__custom--PDLModificationAgreementMember_z0eBliJ4gkEi" title="Interest Expense"&gt;775,000&lt;/span&gt; and $&lt;span id="xdx_90A_eus-gaap--InterestExpense_pp0p0_c20210101__20210331__us-gaap--TypeOfArrangementAxis__custom--PDLModificationAgreementMember_zuwe31a92A08" title="Interest Expense"&gt;775,000&lt;/span&gt;, respectively, was recorded as interest expense on the
accompanying unaudited condensed consolidated financial statements.&lt;/p&gt;

</crvw:AgreementWithPdlBiopharmaTextBlock>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="AsOf2015-06-26_custom_PDLBioPharmaIncMember"
      decimals="-6"
      unitRef="USD">40000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount
      contextRef="AsOf2015-06-26_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="-6"
      unitRef="USD">20000000</us-gaap:DebtInstrumentUnusedBorrowingCapacityAmount>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2015-10-082019-05-13_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="INF"
      unitRef="Pure">0.135</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateStatedPercentage
      contextRef="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="INF"
      unitRef="Pure">0.155</us-gaap:DebtInstrumentInterestRateStatedPercentage>
    <crvw:MinimumCashBalanceRequiredBeforeModification
      contextRef="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">750000</crvw:MinimumCashBalanceRequiredBeforeModification>
    <us-gaap:CompensatingBalanceAmount
      contextRef="AsOf2019-05-15_custom_PDLBioPharmaIncMember_custom_TrancheOneMember"
      decimals="0"
      unitRef="USD">0</us-gaap:CompensatingBalanceAmount>
    <crvw:DeferredIssuanceCosts
      contextRef="AsOf2022-03-31_custom_PDLBioPharmaIncMember_custom_WarrantPurchaseAgreementMember"
      decimals="0"
      unitRef="USD">1600000</crvw:DeferredIssuanceCosts>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-03-31_custom_PDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">775000</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-03-31_custom_PDLModificationAgreementMember"
      decimals="0"
      unitRef="USD">775000</us-gaap:InterestExpense>
    <crvw:AgreementWithHealthcorTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80B_ecustom--AgreementWithHealthcorTextBlock_zMYLUGT5c7H5" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 11 &#x2013; &lt;span id="xdx_82C_zwiUILNiPvkl"&gt;AGREEMENT WITH HEALTHCOR&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;On April 21, 2011, we entered into a Note and Warrant Purchase
Agreement (as subsequently amended) with HealthCor Partners Fund, LP (&#x201c;HealthCor Partners&#x201d;) and HealthCor Hybrid Offshore
Master Fund, LP (&#x201c;HealthCor Hybrid&#x201d; and, together with HealthCor Partners, &#x201c;HealthCor&#x201d;) (the &#x201c;HealthCor
Purchase Agreement&#x201d;). Pursuant to the terms of the HealthCor Purchase Agreement, we sold and issued Senior Secured Convertible Notes
to HealthCor in the principal amount of $&lt;span id="xdx_903_eus-gaap--DebtInstrumentFaceAmount_iI_c20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zr4VLAf7QoE8" title="Loan amount"&gt;9,316,000&lt;/span&gt; and $&lt;span id="xdx_909_eus-gaap--DebtInstrumentFaceAmount_iI_c20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt1Member_z8NzrXNLTwf" title="Loan amount"&gt;10,684,000&lt;/span&gt;, respectively (collectively the &#x201c;2011 HealthCor Notes&#x201d;).
The 2011 HealthCor Notes have a maturity date of April 20, 2021. We also issued Warrants to HealthCor for the purchase of an aggregate
of up to &lt;span id="xdx_908_ecustom--IssuanceOfWarrants_pid_uShares_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zsVjQVFoJ4H7" title="Issuance of warrants"&gt;5,488,456&lt;/span&gt; and &lt;span id="xdx_90F_ecustom--IssuanceOfWarrants_pid_uShares_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt1Member_zKistf6ZvfP1" title="Issuance of warrants"&gt;6,294,403&lt;/span&gt; shares, respectively, of our Common Stock at an exercise price of $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_pid_uUSDPShares_c20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__us-gaap--ConvertibleDebtMember_zwEBERdqP0G1" title="Exercise price of warrants"&gt;1.40&lt;/span&gt; per share (collectively the &#x201c;2011
HealthCor Warrants&#x201d;). So long as no event of default has occurred, the outstanding principal balances of the 2011 HealthCor Notes
accrue interest from April 21, 2011 through April 20, 2016 (the &#x201c;First Five-Year Note Period&#x201d;) at the rate of &lt;span id="xdx_901_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pid_dp_uPure_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt2Member__us-gaap--VariableRateAxis__custom--FirstFiveYearNotePeriodMember_zUWQy3QvvIVj" title="Interest rate"&gt;12.5&lt;/span&gt;% per annum,
compounding quarterly and shall be added to the outstanding principal balances of the 2011 HealthCor Notes on the last day of each calendar
quarter. Interest accruing from April 21, 2016 through April 20, 2021 (the &#x201c;Second Five Year Note Period&#x201d;) at a rate of &lt;span id="xdx_906_eus-gaap--DebtInstrumentInterestRateDuringPeriod_pii_dp_uPure_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt2Member__us-gaap--VariableRateAxis__custom--SecondFiveYearNotePeriodMember_zQJoIZfNXWw6"&gt;10&lt;/span&gt;%
per annum, compounding quarterly, may be paid quarterly in arrears in cash or, at our option, such interest may be added to the outstanding
principal balances of the 2011 HealthCor&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;Notes on the last day of each calendar quarter. For
the period from April 21, 2016 through September 30, 2018 interest has been added to the outstanding principal balance. Pursuant to the
terms of the Ninth Amendment, the accrual of interest has been suspended after September 30, 2018. From the date any event of default
occurs, the interest rate, then applicable, shall be increased by five percent (&lt;span id="xdx_905_eus-gaap--DebtInstrumentInterestRateIncreaseDecrease_pid_dp_uPure_c20110420__20110421__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--LongtermDebtTypeAxis__custom--ConvertibleDebt2Member_zPq6mAteZlyc" title="Increase in interest rate (per annum) should default occur"&gt;5&lt;/span&gt;%) per annum. HealthCor has the right, upon an event
of default, to declare due and payable any unpaid principal amount of the 2011 HealthCor Notes then outstanding, plus previously accrued
but unpaid interest and charges, together with the interest then scheduled to accrue (calculated at the default rate described in the
immediately preceding sentence) through the end of the First Five Year Note Period or the Second Five Year Note Period, as applicable.
Subject to the terms of the Ninth Amendment as discussed below, HealthCor&#x2019;s ability to convert any portion of the outstanding and
unpaid accrued interest on and principal balances of the 2011 HealthCor Notes into fully paid and nonassessable shares of our Common Stock
has been eliminated. The warrants issued with this Note were cancelled with the Ninth-Amendment dated July 10, 2018.&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On April 20, 2021, we agreed with the HealthCor Parties
to (i) amend the 2011 HealthCor Notes to extend the maturity date of the 2011 HealthCor Notes from &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20210417__20210418__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zq4BsK7fj9d3" title="Debt maturity date"&gt;April 20, 2021 &lt;/span&gt;to &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20210419__20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zHgFBfnQCXlj"&gt;April 20, 2022&lt;/span&gt; by
entering into Allonge No. 3 to the 2011 HealthCor Notes (the &#x201c;Third 2011 Note Allonges&#x201d;) and (ii) amend the 2012 HealthCor
Notes to extend the maturity date of the 2012 HealthCor Notes from &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20210417__20210418__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2012Member_zpvZS3c8UFgj"&gt;January 30, 2022&lt;/span&gt; to &lt;span id="xdx_90B_eus-gaap--DebtInstrumentMaturityDate_dd_c20210419__20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2012Member_zdt54U8qF3W7"&gt;April 20, 2022&lt;/span&gt; by entering into Allonge No. 3 to
the 2012 HealthCor Notes (the &#x201c;Third 2012 Note Allonges&#x201d;) (such amendments to the 2011 HealthCor Notes and 2012 HealthCor
Notes together, the &#x201c;HealthCor Note Extensions&#x201d;). In connection with the HealthCor Note Extensions, we issued warrants to
purchase an aggregate of &lt;span id="xdx_904_ecustom--IssuanceOfWarrants_uShares_c20210419__20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zdc0LBHZnobh"&gt;2,000,000&lt;/span&gt; shares of our Common Stock at an exercise price per share equal to $&lt;span id="xdx_906_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zassV7ueuin8"&gt;0.23&lt;/span&gt; per share (subject to adjustment
as described therein) and with an expiration date of &lt;span id="xdx_901_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20210420__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zQeJpbl7Ywo9" title="Warrants expiration date"&gt;April 20, 2031&lt;/span&gt;, to the HealthCor Parties (collectively the &#x201c;2021 HealthCor
Warrants&#x201d;). As a concession has been granted, the agreement is to be accounted for as a troubled debt restructuring by debtors (TDR)
under ASC 470-60.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Also on April 20, 2021, in connection with the HealthCor
Note Extensions and the issuance of the 2021 HealthCor Warrants, we entered into a Consent and Agreement Pursuant to Note and Warrant
Purchase Agreement (the &#x201c;2021 NWPA Consent&#x201d;) with the HealthCor Parties and certain additional Existing Investors (in their
capacity as Majority Holders acting together with the HealthCor Parties), pursuant to which, among other things, (i) the Majority Holders
consented to the HealthCor Note Extensions, (ii) the Majority Holders consented to the issuance of the 2021 HealthCor Warrants and (iii)
the parties agreed that the holders of the 2021 HealthCor Warrants would have registration rights for the shares of Common Stock issuable
upon exercise of the 2021 HealthCor Warrants under the Registration Rights Agreement dated as of April 20, 2011, as amended June 30, 2015,
by and among the Company, the HealthCor Parties and the additional investors party thereto (the &#x201c;Registration Rights Agreement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt TimesNewRoman,serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On March 08, 2022, we agreed with the HealthCor Parties
to (i) amend the 2011 HealthCor Notes to extend the maturity date of the 2011 HealthCor Notes from &lt;span id="xdx_90D_eus-gaap--DebtInstrumentMaturityDate_dd_c20220305__20220306__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zdWc8k9LieN7"&gt;April 20, 2022&lt;/span&gt; to &lt;span id="xdx_905_eus-gaap--DebtInstrumentMaturityDate_dd_c20220307__20220308__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_ztyXsqo7jO48"&gt;April 20, 2023&lt;/span&gt; by
entering into Allonge No. 4 to the 2011 HealthCor Notes (the &#x201c;Third 2011 Note Allonges&#x201d;) and (ii) amend the 2012 HealthCor
Notes to extend the maturity date of the 2012 HealthCor Notes from April 20, 2022 to April 20, 2023 by entering into Allonge No. 4 to
the 2012 HealthCor Notes (the &#x201c;Fourth 2012 Note Allonges&#x201d;) (such amendments to the 2011 HealthCor Notes and 2012 HealthCor
Notes together, the &#x201c;HealthCor Note Extensions&#x201d;). In connection with the HealthCor Note Extensions, we issued warrants to
purchase an aggregate of &lt;span id="xdx_909_ecustom--IssuanceOfWarrants_uShares_c20220307__20220308__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zWzrsttDERT4"&gt;3,000,000&lt;/span&gt; shares of our Common Stock at an exercise price per share equal to $&lt;span id="xdx_90D_eus-gaap--ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1_iI_uUSDPShares_c20220308__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_zcrR4G8nT3Ta"&gt;0.09&lt;/span&gt; per share (subject to adjustment
as described therein) and with an expiration date of &lt;span id="xdx_90E_eus-gaap--WarrantsAndRightsOutstandingMaturityDate_iI_dd_c20220308__srt--CounterpartyNameAxis__custom--HealthCorNoteExtensionsMember_z9z6wANpCa3g"&gt;March 08, 2032&lt;/span&gt;, to the HealthCor Parties (collectively the &#x201c;2021 HealthCor
Warrants&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="font-size: 10pt"&gt;Also on March 08, 2022,
in connection with the HealthCor Note Extensions and the issuance of the 2021 HealthCor Warrants, we entered into a Consent and Agreement
Pursuant to Note and Warrant Purchase Agreement (the &#x201c;2022 NWPA Consent&#x201d;) with the HealthCor Parties and certain additional
Existing Investors (in their capacity as Majority Holders acting together with the HealthCor Parties), pursuant to which, among other
things, (i) the Majority Holders consented to the HealthCor Note Extensions, (ii) the Majority Holders consented to the issuance of the
2021 HealthCor Warrants and (iii) the parties agreed that the holders of the 2021 HealthCor Warrants would have registration rights for
the shares of Common Stock issuable upon&lt;/span&gt; exercise of the 2021 HealthCor Warrants under the Registration Rights Agreement dated
as of April 20, 2011, as amended June 30, 2015, by and among the Company, the HealthCor Parties and the additional investors party thereto
(the &#x201c;Registration Rights Agreement&#x201d;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock_z1w3i5OTnk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zYGlTxxSGhhb"&gt;Below is a summary of the total underlying shares
of common stock related to HealthCor and related investors:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; width: 72%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Investor Group&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 28%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Underlying
    Shares of Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2014 HealthCor Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2014Member_z1O4Bq4MzRI6" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31,752,095&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2015 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2015Member_zcwyqgCeNILd" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,936,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2015 HealthCor Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2015Member_zwRj24AocV5e" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,387,286&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February 2018 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2018InvestorsMember_zw3HtmGXiyPf" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;67,920,722&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 2018 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--July2018InvestorsMember_zEAr9C8anlY3" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31,595,834&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2019
    Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2019Member_zbC53GJEK1wc" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,374,939&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February 2020 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2020InvestorsMember_zAbJzfedSVIf" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,032,645&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIO4UAgzo6Y4" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,999,940&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
&lt;p id="xdx_8A1_z2gIKY6xBu75" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Accounting Treatment&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;When issuing debt or equity securities
convertible into common stock at a discount to the fair value of the common stock at the date the debt or equity financing is
committed, a company is required to record a beneficial conversion feature (&#x201c;BCF&#x201d;) charge. We had three separate
issuances of equity securities convertible into common stock that qualify under this accounting treatment, (i) the 2011 HealthCor
Notes, (ii) the 2012 HealthCor Notes and (iii) the 2014 HealthCor Notes. Because the conversion option and the 2011 HealthCor
Warrants on the 2011 HealthCor Notes were originally classified as a liability when issued due to the down round provision and the
removal of the provision requiring liability treatment, and subsequently reclassified to equity on December 31, 2011 when the 2011
HealthCor Notes were amended, only the accrued interest capitalized as payment in kind (&#x2018;&#x2018;PIK&#x2019;&#x2019;) since
reclassification qualifies under this accounting treatment. We recorded an aggregate of $&lt;span id="xdx_90C_eus-gaap--InterestExpense_c20220101__20220331__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zzO7KKW7R9P2"&gt;406,760&lt;/span&gt; and
$&lt;span id="xdx_90A_eus-gaap--InterestExpense_c20210101__20210331__us-gaap--DebtInstrumentAxis__custom--Notes2011Member_zzvVN4DRv6kb"&gt;1,166,558&lt;/span&gt; in
interest for the three months ended March 31, 2022 and 2021, respectively, related to these transactions. For the three months ended
March 31, 2022 and 2021, we recorded $&lt;span id="xdx_90E_eus-gaap--PaidInKindInterest_c20220101__20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member_zmQ1v9gHDI3f"&gt;806,728 &lt;/span&gt;and
$&lt;span id="xdx_90F_eus-gaap--PaidInKindInterest_c20210101__20210331__srt--CounterpartyNameAxis__custom--HealthCor3Member_z7XQaoI0O287"&gt;721,825&lt;/span&gt;,
respectively, of PIK related to the notes included in the HealthCor Purchase Agreement. The face amount of the 2012 HealthCor Notes,
2014 HealthCor Notes, the Fifth Amendment Notes and the Eighth Amendment Notes and all accrued PIK interest also qualify for BCF
treatment as discussed above. Under the accounting standards, we determined that the restructuring of the HealthCor notes, pursuant
to the terms of the Ninth Amendment, resulted in a troubled debt restructuring. As the future cash flows were greater than the
carrying amount of the debt at the date of the amendment, we accounted for the change prospectively using the new effective interest
rate for three months ended March 31, 2022.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;



&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Warrants were issued with the Fourth, Fifth, Eighth,
Ninth, and Allonge 3 Amendment Notes and the proceeds were allocated to the instruments based on relative fair value as the warrants did
not contain any features requiring liability treatment and therefore were classified as equity. At each amendment date, the warrants were
recorded as debt discount, as a reduction of the net carrying amount of the debt. The debt discounts are amortized into interest expense
each period under the effective interest method. The value allocated to the Ninth Amendment Warrants was $&lt;span id="xdx_909_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorNinthAmendmentWarrantsMember_zntpfaSkaqR" title="Debt discount"&gt;378,000&lt;/span&gt;. The value allocated
to the Allonge 3 Amendment Warrants was $&lt;span id="xdx_902_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorAllongeNo3WarrantsMember_zs4EaVdNvmeb"&gt;420,000&lt;/span&gt;.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Warrants were issued with Allonge 4 Amendment Notes
and the proceeds were allocated to the instruments based on relative fair value as the warrants did not contain any features requiring
lia0bility treatment and therefore were classified as equity. At each amendment date, the warrants were recorded as debt discount, as
a reduction of the net carrying amount of the debt. The debt discounts are amortized into interest expense each period under the effective
interest method. The value allocated to the Allonge 4 Amendment Warrants was $&lt;span id="xdx_90C_eus-gaap--DebtInstrumentUnamortizedDiscount_iI_c20220331__us-gaap--ClassOfWarrantOrRightAxis__custom--HealthCorAllongeNo4WarrantsMember_z7J3g9McB0pf"&gt;240,000&lt;/span&gt;.&lt;/p&gt;

</crvw:AgreementWithHealthcorTextBlock>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember"
      decimals="0"
      unitRef="USD">9316000</us-gaap:DebtInstrumentFaceAmount>
    <us-gaap:DebtInstrumentFaceAmount
      contextRef="AsOf2011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member"
      decimals="0"
      unitRef="USD">10684000</us-gaap:DebtInstrumentFaceAmount>
    <crvw:IssuanceOfWarrants
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      unitRef="Shares">5488456</crvw:IssuanceOfWarrants>
    <crvw:IssuanceOfWarrants
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt1Member"
      decimals="INF"
      unitRef="Shares">6294403</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2011-04-21_custom_HealthCor3Member_us-gaap_ConvertibleDebtMember"
      decimals="INF"
      unitRef="USDPShares">1.40</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_FirstFiveYearNotePeriodMember"
      decimals="INF"
      unitRef="Pure">0.125</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateDuringPeriod
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member_custom_SecondFiveYearNotePeriodMember"
      decimals="INF"
      unitRef="Pure">0.10</us-gaap:DebtInstrumentInterestRateDuringPeriod>
    <us-gaap:DebtInstrumentInterestRateIncreaseDecrease
      contextRef="From2011-04-202011-04-21_custom_HealthCor3Member_custom_ConvertibleDebt2Member"
      decimals="INF"
      unitRef="Pure">0.05</us-gaap:DebtInstrumentInterestRateIncreaseDecrease>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">2021-04-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">2022-04-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-172021-04-18_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">2022-01-30</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember_custom_Notes2012Member">2022-04-20</us-gaap:DebtInstrumentMaturityDate>
    <crvw:IssuanceOfWarrants
      contextRef="From2021-04-192021-04-20_custom_HealthCorNoteExtensionsMember"
      decimals="INF"
      unitRef="Shares">2000000</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2021-04-20_custom_HealthCorNoteExtensionsMember"
      decimals="INF"
      unitRef="USDPShares">0.23</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2021-04-20_custom_HealthCorNoteExtensionsMember">2031-04-20</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-03-052022-03-06_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">2022-04-20</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2022-03-072022-03-08_custom_HealthCorNoteExtensionsMember_custom_Notes2011Member">2023-04-20</us-gaap:DebtInstrumentMaturityDate>
    <crvw:IssuanceOfWarrants
      contextRef="From2022-03-072022-03-08_custom_HealthCorNoteExtensionsMember"
      decimals="INF"
      unitRef="Shares">3000000</crvw:IssuanceOfWarrants>
    <us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1
      contextRef="AsOf2022-03-08_custom_HealthCorNoteExtensionsMember"
      decimals="INF"
      unitRef="USDPShares">0.09</us-gaap:ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1>
    <us-gaap:WarrantsAndRightsOutstandingMaturityDate contextRef="AsOf2022-03-08_custom_HealthCorNoteExtensionsMember">2032-03-08</us-gaap:WarrantsAndRightsOutstandingMaturityDate>
    <crvw:ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_895_ecustom--ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock_z1w3i5OTnk9b" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8BD_zYGlTxxSGhhb"&gt;Below is a summary of the total underlying shares
of common stock related to HealthCor and related investors:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Arial, Helvetica, Sans-Serif; width: 100%; border-collapse: collapse"&gt;
  &lt;tr style="vertical-align: top"&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: center; width: 72%; vertical-align: bottom"&gt;&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;
    &lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: center"&gt;&lt;b&gt;Investor Group&lt;/b&gt;&lt;/p&gt;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; vertical-align: bottom; width: 28%; text-align: center"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;&lt;b&gt;Underlying
    Shares of Common Stock&lt;/b&gt;&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2014 HealthCor Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_989_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2014Member_z1O4Bq4MzRI6" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31,752,095&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2015 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2015Member_zcwyqgCeNILd" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;21,936,419&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2015 HealthCor Notes&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98D_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--HealthCorNotes2015Member_zwRj24AocV5e" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;4,387,286&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February 2018 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_987_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2018InvestorsMember_zw3HtmGXiyPf" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;67,920,722&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;July 2018 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--July2018InvestorsMember_zEAr9C8anlY3" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;31,595,834&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;May 2019
    Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_98B_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--Investors2019Member_zbC53GJEK1wc" style="text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;2,374,939&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;February 2020 Investors&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_988_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember__srt--TitleOfIndividualAxis__custom--February2020InvestorsMember_zAbJzfedSVIf" style="border-bottom: Black 1pt solid; text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;13,032,645&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: top; background-color: White"&gt;
    &lt;td style="text-align: justify"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;TOTAL&lt;/span&gt;&lt;/td&gt;
    &lt;td id="xdx_986_ecustom--OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares_iI_pid_uShares_c20220331__srt--CounterpartyNameAxis__custom--HealthCor3Member__us-gaap--StatementEquityComponentsAxis__us-gaap--CommonStockMember_zIO4UAgzo6Y4" style="border-bottom: Black 2.5pt double; text-align: right" title="Outstanding notes and warrants to purchase common shares"&gt;&lt;span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"&gt;172,999,940&lt;/span&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;
</crvw:ScheduleOfUnderlyingSharesOfCommonStockTableTextBlock>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2014Member"
      decimals="INF"
      unitRef="Shares">31752095</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2015Member"
      decimals="INF"
      unitRef="Shares">21936419</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_HealthCorNotes2015Member"
      decimals="INF"
      unitRef="Shares">4387286</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2018InvestorsMember"
      decimals="INF"
      unitRef="Shares">67920722</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_July2018InvestorsMember"
      decimals="INF"
      unitRef="Shares">31595834</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_Investors2019Member"
      decimals="INF"
      unitRef="Shares">2374939</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember_custom_February2020InvestorsMember"
      decimals="INF"
      unitRef="Shares">13032645</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares
      contextRef="AsOf2022-03-31_custom_HealthCor3Member_us-gaap_CommonStockMember"
      decimals="INF"
      unitRef="Shares">172999940</crvw:OutstandingNotesAndWarrantsUnderlyingNumberOfCommonShares>
    <us-gaap:InterestExpense
      contextRef="From2022-01-012022-03-31_custom_Notes2011Member"
      decimals="0"
      unitRef="USD">406760</us-gaap:InterestExpense>
    <us-gaap:InterestExpense
      contextRef="From2021-01-012021-03-31_custom_Notes2011Member"
      decimals="0"
      unitRef="USD">1166558</us-gaap:InterestExpense>
    <us-gaap:PaidInKindInterest
      contextRef="From2022-01-012022-03-31_custom_HealthCor3Member"
      decimals="0"
      unitRef="USD">806728</us-gaap:PaidInKindInterest>
    <us-gaap:PaidInKindInterest
      contextRef="From2021-01-012021-03-31_custom_HealthCor3Member"
      decimals="0"
      unitRef="USD">721825</us-gaap:PaidInKindInterest>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-03-31_custom_HealthCorNinthAmendmentWarrantsMember"
      decimals="0"
      unitRef="USD">378000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-03-31_custom_HealthCorAllongeNo3WarrantsMember"
      decimals="0"
      unitRef="USD">420000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:DebtInstrumentUnamortizedDiscount
      contextRef="AsOf2022-03-31_custom_HealthCorAllongeNo4WarrantsMember"
      decimals="0"
      unitRef="USD">240000</us-gaap:DebtInstrumentUnamortizedDiscount>
    <us-gaap:EquityMethodInvestmentsDisclosureTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80D_eus-gaap--EquityMethodInvestmentsDisclosureTextBlock_zX6HNJaLGrxi" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 12 &#x2013; &lt;span id="xdx_826_zBHJIyGhlmsb"&gt;JOINT VENTURE AGREEMENT&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 31, 2019, the Company and Rockwell entered
into a Second Amendment to the Rockwell Note (the &#x201c;Second Rockwell Note Amendment&#x201d;) pursuant to which Rockwell agreed to extend
the term of the Rockwell Note by one year, to &lt;span id="xdx_908_eus-gaap--DebtInstrumentMaturityDate_dd_c20191230__20191231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SecondRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zlurT4le34X7" title="Debt maturity date"&gt;December 31, 2020&lt;/span&gt;, and agreed to extend the time to make the quarterly payment that would
otherwise be due on &lt;span id="xdx_906_ecustom--DebtPreviousPaymentDueDate_dd_c20191230__20191231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SecondRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_znjEDDYU3sSg" title="Debt revised payment due date"&gt;December 31, 2019&lt;/span&gt; to &lt;span id="xdx_900_ecustom--DebtRevisedPaymentDueDate_dd_c20191230__20191231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SecondRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zIAZ7E4UtNl3" title="Debt revised payment due date"&gt;January 31, 2020&lt;/span&gt;. We have evaluated the Second Amendment to the Rockwell Note under ASC 470 and
determined that the amendment should be treated as a debt modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On January 31, 2020, the Company and Rockwell entered
into a Third Amendment to the Rockwell Note (the &#x201c;Third Rockwell Note Amendment&#x201d;), pursuant to which Rockwell agreed to extend
the time to make the quarterly payment that would otherwise be due on &lt;span id="xdx_909_ecustom--DebtPreviousPaymentDueDate_dd_c20200130__20200131__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--ThirdRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_z3p7XqIEOrOf" title="Debt previous payment due date"&gt;January 31, 2020&lt;/span&gt; (per the Second Rockwell Note Amendment) to &lt;span id="xdx_90F_ecustom--DebtRevisedPaymentDueDate_dd_c20200130__20200131__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--ThirdRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_z0sYFZ3I9XQ9" title="Debt revised payment due date"&gt;February
10, 2020&lt;/span&gt;. We have evaluated the Third Amendment to the Rockwell Note under ASC 470 and determined that the amendment should be treated
as a debt modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Effective as of March 31, 2020, the Company and Rockwell
entered into a Fourth Amendment to the Rockwell Note (the &#x201c;Fourth Rockwell Note Amendment&#x201d;), pursuant to which Rockwell agreed
to extend the time to make the quarterly payment that would otherwise be due on&lt;span id="xdx_908_ecustom--DebtPreviousPaymentDueDate_dd_c20200330__20200331__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FourthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zXR9lULhZa2g" title="Debt revised payment due date"&gt; March 31, 2020&lt;/span&gt; to &lt;span id="xdx_908_ecustom--DebtRevisedPaymentDueDate_dd_c20200330__20200331__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FourthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zxrefUAHn9ig" title="Debt revised payment due date"&gt;April 16, 2020&lt;/span&gt;. We have evaluated the
Fourth Amendment to the Rockwell Note under ASC 470 and determined that the amendment should be treated as a debt modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On December 31, 2020, the Company and Rockwell entered
a Fifth Amendment to the Rockwell Note (the &#x201c;Fifth Rockwell Note Amendment&#x201d;), pursuant to which Rockwell agreed (i) to extend
the term of the Promissory Note by one (&lt;span id="xdx_90A_ecustom--DebtInstrumentTermExtensionPeriod_dtY_c20201230__20201231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FifthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zNAdtsKCswNi" title="Extend term"&gt;1&lt;/span&gt;) year and continue the quarterly principal payments through &lt;span id="xdx_902_ecustom--DebtInstrumentDateOfFinalRequiredQuarterlyPayment_dd_c20201230__20201231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FifthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zrSOtM6xaoad" title="Date of final required quarterly payment"&gt;September 30, 2021&lt;/span&gt; with the final
balloon payment due on &lt;span id="xdx_90A_eus-gaap--DebtInstrumentMaturityDate_dd_c20201230__20201231__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--FifthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zJheeu8eJTae" title="Debt maturity date"&gt;December 31, 2021&lt;/span&gt; and (ii) that the quarterly principal payment that would otherwise be due on December 31, 2020
will not be required to be made until the final balloon payment due date. We have evaluated the Fourth Amendment to the Rockwell Note
under ASC 470 and determined that the amendment should be treated as a debt modification.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On November&#160;30, 2021, the Company and Rockwell
entered into a Sixth Amendment to the Rockwell Note (the &#x201c;Sixth Rockwell Note Amendment&#x201d;), pursuant to which Rockwell agreed
to extend the term of the Rockwell Note by three months, to &lt;span id="xdx_907_eus-gaap--DebtInstrumentMaturityDate_dd_c20211129__20211130__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SixthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_ztS0ZAEMY4h2"&gt;March 31, 2022&lt;/span&gt;, and agreed that the quarterly principal payment that
would otherwise be due on &lt;span id="xdx_90E_ecustom--DebtPreviousPaymentDueDate_dd_c20211129__20211130__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SixthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zoXmz1uU6s18"&gt;December 31, 2021&lt;/span&gt; will not be required to be made until &lt;span id="xdx_903_ecustom--DebtRevisedPaymentDueDate_dd_c20211129__20211130__srt--CounterpartyNameAxis__custom--RockwellMember__us-gaap--TypeOfArrangementAxis__custom--SixthRockwellNoteAmendmentMember__us-gaap--DebtInstrumentAxis__custom--RockwellNoteMember_zLYeiYFipezj"&gt;March 31, 2022&lt;/span&gt;.&lt;/p&gt;

</us-gaap:EquityMethodInvestmentsDisclosureTextBlock>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-12-31</us-gaap:DebtInstrumentMaturityDate>
    <crvw:DebtPreviousPaymentDueDate contextRef="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">2019-12-31</crvw:DebtPreviousPaymentDueDate>
    <crvw:DebtRevisedPaymentDueDate contextRef="From2019-12-302019-12-31_custom_RockwellMember_custom_SecondRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-01-31</crvw:DebtRevisedPaymentDueDate>
    <crvw:DebtPreviousPaymentDueDate contextRef="From2020-01-302020-01-31_custom_RockwellMember_custom_ThirdRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-01-31</crvw:DebtPreviousPaymentDueDate>
    <crvw:DebtRevisedPaymentDueDate contextRef="From2020-01-302020-01-31_custom_RockwellMember_custom_ThirdRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-02-10</crvw:DebtRevisedPaymentDueDate>
    <crvw:DebtPreviousPaymentDueDate contextRef="From2020-03-302020-03-31_custom_RockwellMember_custom_FourthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-03-31</crvw:DebtPreviousPaymentDueDate>
    <crvw:DebtRevisedPaymentDueDate contextRef="From2020-03-302020-03-31_custom_RockwellMember_custom_FourthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2020-04-16</crvw:DebtRevisedPaymentDueDate>
    <crvw:DebtInstrumentTermExtensionPeriod contextRef="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">P1Y</crvw:DebtInstrumentTermExtensionPeriod>
    <crvw:DebtInstrumentDateOfFinalRequiredQuarterlyPayment contextRef="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2021-09-30</crvw:DebtInstrumentDateOfFinalRequiredQuarterlyPayment>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2020-12-302020-12-31_custom_RockwellMember_custom_FifthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2021-12-31</us-gaap:DebtInstrumentMaturityDate>
    <us-gaap:DebtInstrumentMaturityDate contextRef="From2021-11-292021-11-30_custom_RockwellMember_custom_SixthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2022-03-31</us-gaap:DebtInstrumentMaturityDate>
    <crvw:DebtPreviousPaymentDueDate contextRef="From2021-11-292021-11-30_custom_RockwellMember_custom_SixthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2021-12-31</crvw:DebtPreviousPaymentDueDate>
    <crvw:DebtRevisedPaymentDueDate contextRef="From2021-11-292021-11-30_custom_RockwellMember_custom_SixthRockwellNoteAmendmentMember_custom_RockwellNoteMember">2022-03-31</crvw:DebtRevisedPaymentDueDate>
    <us-gaap:LesseeOperatingLeasesTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_80B_eus-gaap--LesseeOperatingLeasesTextBlock_zarYp7tv56Ek" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 13 &#x2013; &lt;span id="xdx_823_zn47FRThzxYe"&gt;LEASE&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;Under ASC Topic 842, Leases (&#x201c;ASC 842&#x201d;),
operating lease expense is generally recognized evenly over the term of the lease. The Company has an operating lease primarily consisting
of office space with remaining lease term of &lt;span id="xdx_902_eus-gaap--LesseeOperatingLeaseRemainingLeaseTerm_iI_dtM_c20220331_zr7MTpv1p2g3" title="Remaining lease term"&gt;41&lt;/span&gt; months (Lease through &lt;span id="xdx_902_eus-gaap--LeaseExpirationDate1_dd_c20220101__20220331_zvA3DOdyH6vh"&gt;August 31, 2025&lt;/span&gt;).&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;On September 8, 2009, we entered into a Commercial
Lease Agreement (the &#x201c;Lease&#x201d;) for &lt;span id="xdx_908_ecustom--AreaOfLeasedProperty_iI_dd_uSqft_c20090908_zeewzW1RYEee" title="Area of lease"&gt;10,578&lt;/span&gt; square feet of office and warehouse space expiring on &lt;span id="xdx_907_eus-gaap--LeaseExpirationDate1_dd_c20090907__20090908_zjjmF7Q7zyze"&gt;June 30, 2015&lt;/span&gt;. On March 4,
2020, we entered into the Fourth Amendment to Commercial Lease Agreement (the &#x201c;Lease Extension&#x201d;), wherein we extended the
Lease through &lt;span id="xdx_90B_eus-gaap--LeaseExpirationDate1_dd_c20200303__20200304_zn9blUlOGUzg" title="Expiration of lease"&gt;August 31, 2025&lt;/span&gt;. The Lease Extension contains a renewal provision under which the Lease has been extended for an additional
&lt;span id="xdx_905_eus-gaap--LesseeOperatingLeaseRenewalTerm_iI_dxL_c20200304_z9uIDlqFt745" title="Lease renewal term::XDX::P5Y"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0870"&gt;five-year&lt;/span&gt;&lt;/span&gt; period under the same terms and conditions of the original Lease Agreement. Management has identified this extension as a reassessment
event, as we have elected to exercise the Lease Extension option even though the Company had previously determined that it was not reasonably
certain to do so.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;The Company has reassessed the discount rate at the
remeasurement date, at &lt;span id="xdx_904_eus-gaap--LesseeOperatingLeaseDiscountRate_iI_dp_uPure_c20220331_ztYxv2KDXRPd" title="Discount rate"&gt;14.8&lt;/span&gt;% and the Company has remeasured its ROU asset and lease liability on our balance sheet using the discount
rate that applies as of the date of the reassessment event to remeasure its Operating lease asset and lease liability. The reassessment
is based on the remaining lease term and lease payments. The Company has further concluded that the Lease Extension has no effects on
the classification of the Lease. Rent expense for the three months ended March 31, 2022 and 2021 was $&lt;span id="xdx_900_eus-gaap--OperatingLeaseCost_c20220101__20220331_zsvftfE9w383" title="Rent expense"&gt;82,706&lt;/span&gt; and $&lt;span id="xdx_905_eus-gaap--OperatingLeaseCost_c20210101__20210331_z3NreDpTM13f" title="Rent expense"&gt;72,684&lt;/span&gt;, respectively.&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Lease Position&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_895_ecustom--LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock_zg8qGHic0Cc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zIrZcCu2q25g"&gt;Operating lease asset and liability for our operating
lease were recorded in the condensed consolidated balance sheet as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20220331_zHlZX6ezUjed" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of &lt;br/&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20211231_zxrienNYOBQf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of &lt;br/&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AssetsAbstract_iB_zlr8gczC4c27" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maLAzmIW_zxIphZv3xgk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;526,652&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;555,150&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LeaseAssets_i01TI_mtLAzmIW_zyw9bpnKgMPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Total lease asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;526,652&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;555,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesAbstract_iB_z8Cih3wjQb2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_zPGED2EPsQY6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maOLLz5MW_zpPdLeqv8QP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;165,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;162,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zoib2FB7fLBh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Long-term liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;Operating lease liability, net of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;current portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maOLLz5MW_c20220331_zgZBugdmpr68" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, net of current portion"&gt;412,557&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maOLLz5MW_c20211231_zJXIg40HMGY" style="border-bottom: Black 1pt solid; text-align: right"&gt;445,033&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLz5MW_zqmGErfz1mZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;578,298&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;607,503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AF_zztu9xDeQUal" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;




&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span style="text-decoration: underline"&gt;Undiscounted Cash Flows&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ziHeWFinNE25" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BB_zwkApA8r1EPf"&gt;Future lease payments included in the measurement of operating lease liability
on the condensed consolidated balance sheet as of March 31, 2022, for the following five fiscal years and thereafter as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quarter ending &lt;br/&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Operating &lt;br/&gt;Leases&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Remaining 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOpLease_c20220331_zISikRXO5Isc" style="width: 20%; text-align: right" title="Remaining 2022"&gt;165,741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOpLease_c20220331_zxpeeccQo9dg" style="text-align: right" title="2023"&gt;211,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOpLease_c20220331_zy5sJpoXdXoc" style="text-align: right" title="2024"&gt;217,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOpLease_c20220331_zQop12uV78Lc" style="border-bottom: Black 1pt solid; text-align: right" title="2025"&gt;148,447&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOpLease_c20220331_z2Z6V2ZHBGcb" style="text-align: right" title="Total minimum lease payments"&gt;743,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;Less effects of discounting&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20220331_zJdmIZzi19Y1" style="border-bottom: Black 1pt solid; text-align: right" title="Less effects of discounting"&gt;(165,134&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_dxL_c20220331_zgvjiQTF4vMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of future minimum lease payments::XDX::578%2C298"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;578,299&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8AD_zmNekNtGVcIi" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span style="text-decoration: underline"&gt;Cash Flows&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;p id="xdx_89A_ecustom--LesseeOperatingLeaseCashFlowInformationTableTextBlock_zc9VRIDB5b82" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B5_z1KULT7RTuIl"&gt;The table below presents certain information related
to the cash flows for the Company&#x2019;s operating lease for the three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20220101__20220331_zpuUyhrBHES2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zItqJh1WWPA1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeasePayments_i01_zV1LfFkhHaFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;29,205&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

&lt;p id="xdx_8A3_zJchCgoEr066" style="margin-top: 0; margin-bottom: 0"&gt;&#160;&lt;/p&gt;

</us-gaap:LesseeOperatingLeasesTextBlock>
    <us-gaap:LesseeOperatingLeaseRemainingLeaseTerm contextRef="AsOf2022-03-31">P41M</us-gaap:LesseeOperatingLeaseRemainingLeaseTerm>
    <us-gaap:LeaseExpirationDate1 contextRef="From2022-01-01to2022-03-31">2025-08-31</us-gaap:LeaseExpirationDate1>
    <crvw:AreaOfLeasedProperty contextRef="AsOf2009-09-08" decimals="INF" unitRef="Sqft">10578</crvw:AreaOfLeasedProperty>
    <us-gaap:LeaseExpirationDate1 contextRef="From2009-09-072009-09-08">2015-06-30</us-gaap:LeaseExpirationDate1>
    <us-gaap:LeaseExpirationDate1 contextRef="From2020-03-032020-03-04">2025-08-31</us-gaap:LeaseExpirationDate1>
    <us-gaap:LesseeOperatingLeaseDiscountRate contextRef="AsOf2022-03-31" decimals="INF" unitRef="Pure">0.148</us-gaap:LesseeOperatingLeaseDiscountRate>
    <us-gaap:OperatingLeaseCost
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">82706</us-gaap:OperatingLeaseCost>
    <us-gaap:OperatingLeaseCost
      contextRef="From2021-01-012021-03-31"
      decimals="0"
      unitRef="USD">72684</us-gaap:OperatingLeaseCost>
    <crvw:LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_895_ecustom--LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock_zg8qGHic0Cc8" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B0_zIrZcCu2q25g"&gt;Operating lease asset and liability for our operating
lease were recorded in the condensed consolidated balance sheet as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 95%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: justify"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20220331_zHlZX6ezUjed" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of &lt;br/&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_497_20211231_zxrienNYOBQf" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;As of &lt;br/&gt;December 31, 2021&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40F_eus-gaap--AssetsAbstract_iB_zlr8gczC4c27" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Assets&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_407_eus-gaap--OperatingLeaseRightOfUseAsset_i01I_maLAzmIW_zxIphZv3xgk3" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="width: 56%; text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;Operating lease asset&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;526,652&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 8%; padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 1pt solid; width: 12%; text-align: right"&gt;555,150&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_ecustom--LeaseAssets_i01TI_mtLAzmIW_zyw9bpnKgMPl" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Total lease asset&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;526,652&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;555,150&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40B_eus-gaap--LiabilitiesAbstract_iB_z8Cih3wjQb2j" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="padding-left: 5.4pt"&gt;Liabilities&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--LiabilitiesCurrentAbstract_i01B_zPGED2EPsQY6" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Current liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40C_eus-gaap--OperatingLeaseLiabilityCurrent_i02I_maOLLz5MW_zpPdLeqv8QP8" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;Operating lease liability&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;165,741&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;$&lt;/td&gt;&lt;td style="text-align: right"&gt;162,470&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_40E_eus-gaap--LiabilitiesNoncurrentAbstract_i01B_zoib2FB7fLBh" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;Long-term liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-left: 5.4pt"&gt;&#160;&#160;Operating lease liability, net of&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left; padding-bottom: 1pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;&#160;&#160;&#160;current portion&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maOLLz5MW_c20220331_zgZBugdmpr68" style="border-bottom: Black 1pt solid; text-align: right" title="Operating lease liability, net of current portion"&gt;412,557&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiabilityNoncurrent_i02I_maOLLz5MW_c20211231_zJXIg40HMGY" style="border-bottom: Black 1pt solid; text-align: right"&gt;445,033&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_409_eus-gaap--OperatingLeaseLiability_i01TI_mtOLLz5MW_zqmGErfz1mZ4" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left; padding-bottom: 2.5pt; padding-left: 5.4pt"&gt;&#160;&#160;&#160;&#160;Total lease liability&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;578,298&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; text-align: right"&gt;607,503&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</crvw:LesseeOperatingLeaseRightOfUseAssetAndLiabilityTableTextBlock>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">526652</us-gaap:OperatingLeaseRightOfUseAsset>
    <us-gaap:OperatingLeaseRightOfUseAsset contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">555150</us-gaap:OperatingLeaseRightOfUseAsset>
    <crvw:LeaseAssets contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">526652</crvw:LeaseAssets>
    <crvw:LeaseAssets contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">555150</crvw:LeaseAssets>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">165741</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityCurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">162470</us-gaap:OperatingLeaseLiabilityCurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">412557</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiabilityNoncurrent contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">445033</us-gaap:OperatingLeaseLiabilityNoncurrent>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">578298</us-gaap:OperatingLeaseLiability>
    <us-gaap:OperatingLeaseLiability contextRef="AsOf2021-12-31" decimals="0" unitRef="USD">607503</us-gaap:OperatingLeaseLiability>
    <us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_894_eus-gaap--LesseeOperatingLeaseLiabilityMaturityTableTextBlock_ziHeWFinNE25" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;span id="xdx_8BB_zwkApA8r1EPf"&gt;Future lease payments included in the measurement of operating lease liability
on the condensed consolidated balance sheet as of March 31, 2022, for the following five fiscal years and thereafter as follows:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-indent: 0.5in"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 65%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Quarter ending &lt;br/&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Operating &lt;br/&gt;Leases&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Remaining 2022&lt;/span&gt;&lt;/td&gt;&lt;td style="width: 2%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="width: 4%"&gt;&#160;&lt;/td&gt;
    &lt;td style="width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98F_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear_iI_maOpLease_c20220331_zISikRXO5Isc" style="width: 20%; text-align: right" title="Remaining 2022"&gt;165,741&lt;/td&gt;&lt;td style="width: 1%; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;2023&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_981_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths_iI_maOpLease_c20220331_zxpeeccQo9dg" style="text-align: right" title="2023"&gt;211,451&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;2024&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_98E_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearTwo_iI_maOpLease_c20220331_zy5sJpoXdXoc" style="text-align: right" title="2024"&gt;217,794&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;2025&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_987_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDueYearThree_iI_maOpLease_c20220331_zQop12uV78Lc" style="border-bottom: Black 1pt solid; text-align: right" title="2025"&gt;148,447&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Total minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_986_eus-gaap--LesseeOperatingLeaseLiabilityPaymentsDue_iTI_mtOpLease_c20220331_z2Z6V2ZHBGcb" style="text-align: right" title="Total minimum lease payments"&gt;743,433&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;&#160;&#160;&#160;&#160;&#160;Less effects of discounting&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 1pt solid; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td id="xdx_984_eus-gaap--LesseeOperatingLeaseLiabilityUndiscountedExcessAmount_iNI_di_c20220331_zJdmIZzi19Y1" style="border-bottom: Black 1pt solid; text-align: right" title="Less effects of discounting"&gt;(165,134&lt;/td&gt;&lt;td style="padding-bottom: 1pt; text-align: left"&gt;)&lt;/td&gt;&lt;/tr&gt;
  &lt;tr style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="white-space: nowrap; text-align: left"&gt;&lt;span style="font-size: 10pt"&gt;Present value of future minimum lease payments&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; text-align: left"&gt;$&lt;/td&gt;&lt;td id="xdx_98A_eus-gaap--OperatingLeaseLiability_iI_dxL_c20220331_zgvjiQTF4vMa" style="border-bottom: Black 2.5pt double; text-align: right" title="Present value of future minimum lease payments::XDX::578%2C298"&gt;&lt;span style="-sec-ix-hidden: xdx2ixbrl0921"&gt;578,299&lt;/span&gt;&lt;/td&gt;&lt;td style="padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</us-gaap:LesseeOperatingLeaseLiabilityMaturityTableTextBlock>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">165741</us-gaap:LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">211451</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">217794</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearTwo>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">148447</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueYearThree>
    <us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">743433</us-gaap:LesseeOperatingLeaseLiabilityPaymentsDue>
    <us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount contextRef="AsOf2022-03-31" decimals="0" unitRef="USD">165134</us-gaap:LesseeOperatingLeaseLiabilityUndiscountedExcessAmount>
    <crvw:LesseeOperatingLeaseCashFlowInformationTableTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_89A_ecustom--LesseeOperatingLeaseCashFlowInformationTableTextBlock_zc9VRIDB5b82" style="font: 10pt Times New Roman, Times, Serif; margin: 0; text-align: justify"&gt;&lt;span id="xdx_8B5_z1KULT7RTuIl"&gt;The table below presents certain information related
to the cash flows for the Company&#x2019;s operating lease for the three months ended March 31, 2022:&lt;/span&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-left: auto; border-collapse: collapse; width: 75%; margin-right: auto"&gt;
  &lt;tr style="vertical-align: bottom"&gt;
    &lt;td style="text-align: center"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;&lt;td style="padding-bottom: 1pt"&gt;&lt;b&gt;&#160;&lt;/b&gt;&lt;/td&gt;
    &lt;td colspan="3" id="xdx_499_20220101__20220331_zpuUyhrBHES2" style="border-bottom: Black 1pt solid; text-align: center"&gt;&lt;b&gt;Three Months Ended &lt;br/&gt;March 31, 2022&lt;/b&gt;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_408_eus-gaap--CashFlowOperatingActivitiesLesseeAbstract_iB_zItqJh1WWPA1" style="vertical-align: bottom; background-color: White"&gt;
    &lt;td style="padding-left: 9pt; text-align: justify; text-indent: -9pt"&gt;Cash paid for amounts included in the measurement of lease liabilities:&lt;/td&gt;&lt;td&gt;&#160;&lt;/td&gt;
    &lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: right"&gt;&#160;&lt;/td&gt;&lt;td style="text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;tr id="xdx_400_eus-gaap--OperatingLeasePayments_i01_zV1LfFkhHaFg" style="vertical-align: bottom; background-color: rgb(204,238,255)"&gt;
    &lt;td style="width: 70%; text-align: justify; padding-bottom: 2.5pt"&gt;&#160;&#160;&#160;&#160;&#160;Operating cash flows for operating leases&lt;/td&gt;&lt;td style="width: 10%; padding-bottom: 2.5pt"&gt;&#160;&lt;/td&gt;
    &lt;td style="border-bottom: Black 2.5pt double; width: 1%; text-align: left"&gt;$&lt;/td&gt;&lt;td style="border-bottom: Black 2.5pt double; width: 18%; text-align: right"&gt;29,205&lt;/td&gt;&lt;td style="width: 1%; padding-bottom: 2.5pt; text-align: left"&gt;&#160;&lt;/td&gt;&lt;/tr&gt;
  &lt;/table&gt;

</crvw:LesseeOperatingLeaseCashFlowInformationTableTextBlock>
    <us-gaap:OperatingLeasePayments
      contextRef="From2022-01-01to2022-03-31"
      decimals="0"
      unitRef="USD">29205</us-gaap:OperatingLeasePayments>
    <us-gaap:SubsequentEventsTextBlock contextRef="From2022-01-01to2022-03-31">&lt;p id="xdx_808_eus-gaap--SubsequentEventsTextBlock_z0ulrKNbVTyh" style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&lt;b&gt;&lt;span style="text-decoration: underline"&gt;NOTE 15 &#x2013; &lt;span id="xdx_821_zSyUmPc74fw8"&gt;SUBSEQUENT EVENTS&lt;/span&gt;&lt;/span&gt;&lt;/b&gt;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;&#160;&lt;/p&gt;

&lt;p style="font: 10pt Times New Roman, Times, Serif; margin: 0"&gt;The Company has evaluated subsequent events through May 26, 2022, the date
of filing of this Form 10-Q.&lt;/p&gt;

</us-gaap:SubsequentEventsTextBlock>
    <link:footnoteLink
      xlink:role="http://www.xbrl.org/2003/role/link"
      xlink:type="extended">
        <link:loc
          xlink:href="#Fact000730"
          xlink:label="Fact000730"
          xlink:type="locator"/>
        <link:footnote id="Footnote000747" xlink:label="Footnote000747" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Salary for Steve Johnson, CEO, between
February 15, 2018 and September 30, 2020.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000730"
          xlink:to="Footnote000747"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000731"
          xlink:label="Fact000731"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000731"
          xlink:to="Footnote000747"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#xdx2ixbrl0739"
          xlink:label="xdx2ixbrl0739"
          xlink:type="locator"/>
        <link:footnote id="Footnote000748" xlink:label="Footnote000748" xlink:role="http://www.xbrl.org/2003/role/footnote" xlink:type="resource" xml:lang="en-US">Renewal of directors and officer&#x2019;s
insurance.</link:footnote>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="xdx2ixbrl0739"
          xlink:to="Footnote000748"
          xlink:type="arc"/>
        <link:loc
          xlink:href="#Fact000740"
          xlink:label="Fact000740"
          xlink:type="locator"/>
        <link:footnoteArc
          xlink:arcrole="http://www.xbrl.org/2003/arcrole/fact-footnote"
          xlink:from="Fact000740"
          xlink:to="Footnote000748"
          xlink:type="arc"/>
    </link:footnoteLink>
</xbrl>
